



Cite this: *Chem. Soc. Rev.*, 2024, 53, 3327

Intracellular microbial rhodopsin-based optogenetics to control metabolism and cell signaling†

Anastasiia D. Vlasova, ^a Siarhei M. Bukhalovich, ^a Diana F. Bagaeva, ^a Aleksandra P. Polyakova, ^a Nikolay S. Ilyinsky, ^a Semen V. Nesterov, ^a Fedor M. Tsybrov, ^a Andrey O. Bogorodskiy, ^a Egor V. Zinovev, ^a Anatolii E. Mikhailov, ^a Alexey V. Vlasov, ^{ab} Alexander I. Kuklin, ^{ab} Valentin I. Borshchevskiy, ^{ab} Ernst Bamberg, ^c Vladimir N. Uversky ^d and Valentin I. Gordeliy ^{*e}

Microbial rhodopsin (MRs) ion channels and pumps have become invaluable optogenetic tools for neuroscience as well as biomedical applications. Recently, MR-optogenetics expanded towards subcellular organelles opening principally new opportunities in optogenetic control of intracellular metabolism and signaling via precise manipulations of organelle ion gradients using light. This new optogenetic field expands the opportunities for basic and medical studies of cancer, cardiovascular, and metabolic disorders, providing more detailed and accurate control of cell physiology. This review summarizes recent advances in studies of the cellular metabolic processes and signaling mediated by optogenetic tools targeting mitochondria, endoplasmic reticulum (ER), lysosomes, and synaptic vesicles. Finally, we discuss perspectives of such an optogenetic approach in both fundamental and applied research.

Received 27th August 2023

DOI: 10.1039/d3cs00699a

rsc.li/chem-soc-rev

^a Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, Russia

^b Frank Laboratory of Neutron Physics, Joint Institute for Nuclear Research, Dubna, Russia

^c Max Planck Institute of Biophysics, Frankfurt am Main, Germany

^d Department of Molecular Medicine and Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

E-mail: vversky@usf.edu

^e Institut de Biologie Structurale Jean-Pierre Ebel, Université Grenoble Alpes-Commissariat à l'Energie Atomique et aux Energies Alternatives-CNRS, 38027 Grenoble, France.

E-mail: valentin.gordeliy@ibs.fr

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cs00699a>



Anastasiia D. Vlasova

Dr. Anastasiia D. Vlasova has recently defended her PhD thesis on rhodopsin proton pumps and ion channels for optogenetic control of cytosolic pH and mitochondrial physiology. Anastasiia now works on the development of organelle optogenetics in the Laboratory for Cellular Molecular Biology and Optogenetics at the Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology.



Siarhei M. Bukhalovich

Siarhei M. Bukhalovich is a PhD student at Moscow Institute of Physics and Technology (MIPT) doing his PhD about rhodopsins and optogenetics. He completed his bachelor's and master's degrees at MIPT. Siarhei now works on the search and development of new optogenetic tools in the Laboratory for Cellular Molecular Biology and Optogenetics at the Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology.



Introduction

Optogenetics is a rapidly developing interdisciplinary field focused on the control of cellular physiological processes using light.^{1–3} Initially, optogenetics was developed as an instrument to control excitable cells, especially neurons.^{4,5} Microbial rhodopsin (MR)-based optogenetic tools are expressed in the plasma membrane of excitable cells, where they are capable of inducing firing or silencing of neuronal cells in culture, tissue or brain of living animals.^{6,7} A vast variety of genes of MRs (more than 10 000) were found in all domains of life and even in viruses.^{8,9} This natural variability offers considerable potential for further search and development of new MR optogenetic tools.

MR-based optogenetic tools differ in light sensitivity, ion permeability, pumping selectivity, kinetics, spectral properties,

level and selectivity of expression. The toolkit of the optogenetic approach, targeting the plasma membrane, can be expanded by a selective targeting of optogenetic tools to membrane organelles of eukaryotic cells. Targeted expression is a promising emerging approach of precise control of membrane permeability and ion gradients in specific organelles. It provides the means of noninvasive, fast, and reversible control of cell physiology. Although artificial selective targeting of membrane proteins is challenging, successful expression opens new ways to investigate organelle functions and dysfunctions in pathologies, including age-related diseases. The organelle optogenetic approach might be potentially implemented for studies of cancer, cardiovascular, and metabolic disorders.

Recent studies support the amazing potential of MRs in optogenetic applications. Namely, MRs can provide control of a



Diana F. Bagaeva

Diana F. Bagaeva graduated from Moscow State University with a bachelor's degree in 2019 and from Moscow Institute of Physics and Technology (MIPT) with a master's degree in Biotechnology in 2022. She is a PhD student at MIPT doing her PhD on the topic of Optogenetics and Neurobiology. Her current research interests include optogenetic influences on synaptic functions. Now Diana works in the Laboratory for Cellular Molecular Biology and Optogenetics at the Research Center for Molecular Mechanisms of Aging and Age-Related Diseases.



Aleksandra P. Polyakova

Aleksandra P. Polyakova is a PhD student at Moscow Institute of Physics and Technology (MIPT) doing her PhD in Optogenetic and Neurobiology. She graduated from MIPT in 2023 with MS in Biotechnology. Aleksandra currently works on developing a new approach to analyse ion homeostasis and modulate neuronal excitation in epilepsy models using specific light-driven proteins and genetically encoded biosensors.



Valentin I. Borshchevskiy

Dr. Valentin I. Borshchevskiy is a specialist in structural biology and protein dynamics, focusing on retinal membrane proteins and G protein-coupled receptors. His research is dedicated to advancing optogenetic approaches and structure-based rational drug design. Dr. Borshchevskiy co-authors over 90 publications and has been nominated for the Yu. Struchkov Prize and the Young Scientist Award 2021 of the European Synchrotron. Dr. Borshchevskiy is the Head of the Laboratory for Biomolecular Structure and Dynamics, as well as the Vice-Head of the Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, both located at the Moscow Institute of Physics and Technology.



Ernst Bamberg

Prof. Dr. Ernst Bamberg is an expert in functional and structural analysis of electrogenic membrane proteins with a focus on light-sensitive rhodopsin-like proteins. Prof. Bamberg is one of the pioneers of optogenetics, which has revolutionized neuroscience and in part cell biology, and is a Clarivate (Web of Science) Citation Laureate in Physiology or Medicine in 2019.



number of cellular processes through organelle optogenetics with low-invasiveness, high time/spatial resolution, and unique selectivity.² Non-rhodopsin optogenetics is also a rapidly expanding field,^{10,11} which uses other photosensitive proteins to selectively control intermolecular interactions, providing an ability to control a plethora of processes by light. These processes include transcription,¹² receptor positioning,¹³ activation,¹⁴ signal transduction,¹⁵ cytoskeletal dynamics and organelle positioning,¹⁶ programmed cell death,¹⁷ biogenesis¹⁸ and composition of membraneless organelles,¹⁹ as well as phase-separation propensities of proteins in living cells,²⁰ and many other processes.¹⁰ In contrast, MR-optogenetics allows one to directly control the permeability of biological membranes of subcellular compartments and subsequent ion gradients. Potentially, both approaches can be complementary used for expanding control of cellular functions at subcellular scale.

Light-driven channelrhodopsins have revolutionized neuroscience.²¹ The progress did not stop there; moreover, as the optogenetic toolkit expanded dramatically and became more diversified, it provides important grounds for the rapid growth of optogenetic applications.³ Several recent reviews describe this progress.^{2,10,22} However, there is still a lack of comprehensive reviews on MR intracellular optogenetics.

This review focuses on optogenetics based on the targeted expression of MRs in intracellular membrane compartments. This area of research dramatically expands possibilities of cellular physiology control. However, targeting of exogenous membrane proteins in cell organelles remains challenging.²³ Therefore, this review describes general strategies for protein targeting based on the addition of signal sequences driving proteins to the membranes of a desirable cellular compartment.²⁴ Finally, the article discusses the perspectives of optogenetics in both fundamental and applied research.

Structure and functions of microbial rhodopsins

A detailed description of the structural features and functionality of proteins utilized in intracellular optogenetics is outside the scope of this article, and interested readers are addressed to multiple corresponding reviews discussing structural and functional peculiarities of rhodopsins, also known as retinylidene proteins (*e.g.*, ref. 25–31). Nevertheless, we present here some basic information on the structural organization of this biologically relevant protein superfamily, members of which are found in *Eukaryotes*, *Bacteria*, and *Archaea*.

Despite the fact that MRs can function as pumps, channels, and light-sensors,²⁷ they all have a common structural organization typical for all the rhodopsin superfamily members, where the chromophore retinal is covalently bound to an internal pocket formed by the seven membrane-embedded α -helices (7TM) of the opsin apoprotein.³⁰ Light absorption induces isomerization of all-*trans*-retinal to 13-*cis*-retinal in microbial rhodopsins (11-*cis*-retinal to all-*trans*-retinal in animal rhodopsins) that culminate with protein conformational changes leading to the rhodopsin activation.³⁰ The unique photophysical and photochemical processes required for optimal light to energy or light to signal conversion in rhodopsins are defined by specific chromophore-protein interactions.²⁷ For example, the 7TM protein scaffold of microbial rhodopsins is suitable for light-driven ion pumps, light-gated ion channels, and light sensors which couple to membrane or soluble transducer proteins.²⁹

In the comprehensive review, Ernst *et al.*²⁷ emphasized: “While all of the known structures of microbial rhodopsins show a common tight α -helical bundle of 7TM helices surrounding the retinal chromophore, there is substantial variation in the arrangement of side chains, the structure of the



Vladimir N. Uversky

Prof. Vladimir N. Uversky is an expert in protein physics and works on protein intrinsic disorder phenomenon and analysis of protein folding and misfolding. He has authored over 1150 scientific publications and edited several books and book series related to protein science. He has been listed as a Web of Science Highly Cited Researcher every year from 2014 to 2020. In 2021, he was elected as a Fellow of the Royal Society of Biology

and a Fellow of the Royal Society of Chemistry. He collaborated with more than 12,500 colleagues from more than 2,750 research organizations in 89 countries/territories.



Valentin I. Gordeliy

Prof. Dr. Valentin I. Gordeliy is a Research Director at the Institute of Structural Biology, Grenoble. He was a founder of the Center of Molecular Mechanisms of Aging at Moscow Institute of Physics and Technology (State University), a professor at the University of Aachen and a Helmholtz professor at the Research Center Juelich. Beginning with physics and biophysics he moved later to structural biology and mechanisms of membrane proteins. He contributed to the understanding of molecular

mechanisms of two-component signaling systems, proton transfer and rhodopsins, like channelrhodopsins. A significant piece of his current research is devoted to the discovery, characterization and applications of new rhodopsin-based optogenetic tools.





Fig. 1 (A) Structure of bacteriorhodopsin (BR), with conserved aromatic residues highlighted (PDB ID: 1QM8). Tyr83, Trp86, and Trp182 are strongly conserved among microbial rhodopsins (orange). Aromatic amino acids are strongly conserved at the position of Tyr185, Trp189, and Phe219 (yellow). In BR, Trp86, Trp182, Tyr185, and Trp189 constitute the chromophore binding pocket for all-*trans*-retinal (gray). (B) Crystallographically observed internal water molecules of BR (shown as green spheres). Note much higher hydration of the extracellular half (bottom) compared to the cytoplasmic one (top). Adapted from Ernst *et al.*²⁷

interfacial regions and loops, as well as in the positions of internal water molecules".^{28,29,32} The most conserved common element in the rhodopsin structure is the retinal binding pocket. Importance of local structural organization for the energy transfer between retinal and opsin is illustrated in Fig. 1 representing the overall structure of bacteriorhodopsin (BR) and showing localization of the functionally important conserved aromatic amino acids.

Here, all-*trans*-retinal is sandwiched between the strongly conserved Trp86 and Trp182 that form an important part of the chromophore binding site.²⁷ It was suggested that the isomerization pathway from the all-*trans* to 13-*cis*-retinal is determined by these bulky groups, whereas the functionally important changes of the helical tilts necessary for BR function are triggered by the interaction of the photoisomerized retinal with Trp182 acting as a mechanical transducer for passing the energy stored in retinal deformation.³³ In the BR retinal binding pocket, Tyr185 occupies another important position, participating in hydrogen-bonding stabilization of the protonated retinal Schiff base (RSBH⁺) counterion.²⁷ As shown in Fig. 1B, all microbial rhodopsins contain protein-bound water molecules near the retinal Schiff base (RSB), contributing to the stabilization of the RSBH⁺ in the hydrophobic protein interior and thereby playing crucial roles in protein function.²⁷

Abbreviated (un)structural overview of optogenetics

The section below represents an abbreviated glance at the (un)structured biology of MRs discussed in this review. Although the core MR structure is represented by a 7TM helix architecture with three loop regions on both the extracellular and the cytoplasmic sides of the membrane, and although this

module is typically used in optogenetics. Fig. 2 shows that many rhodopsins have regions of varying lengths extending beyond their 7TM core architecture (see red segments in Fig. 2a). Curiously, these “extra” pieces represent appendices that are typically expected to be highly disordered (as evaluated by PONDR[®] VSL2³⁴). Fig. 2a also shows that the most disorder in the most extended rhodopsins is concentrated in their C-terminal (cytoplasmic) tails. It is tempting to speculate that these disordered tails might serve as binding platforms for the disorder-based interaction of rhodopsins with specific partners. In line with this hypothesis, each of the four longest rhodopsins discussed in this article contains multiple molecular recognition features, MoRFs, *i.e.*, disordered segments capable of disorder-to-order transitions associated with binding of specific partners, as evaluated using the IUPred2A platform³⁵ (data not shown).

Furthermore, Fig. 2b shows the correlation between intrinsic disorder content and protein length and gives a clear indication that most of the “extra” length added to the 7TM core in rhodopsin is materialized in disordered regions. Although the 7TM core is predicted to be mostly ordered, this transmembrane segment includes some flexible regions that correspond to the loops linking the transmembrane helices. Curiously, these loop regions in different rhodopsins show rather different propensities for conformational flexibility (data not shown), suggesting different roles of said conformational flexibility in the functionality of these proteins.

The fact that the cytoplasmic tails of rhodopsins contain high levels of intrinsic disorder is in line with the known peculiarities of disorder distribution within the transmembrane proteins. In fact, it was reported that 50% of transmembrane proteins have at least one intrinsically disordered region (IDR) of 30 amino acids or more, with such disordered domains being preferentially localized to the cytoplasmic side especially of the multipass transmembrane proteins.³⁶ In addition to possessing numerous MoRFs, the IDRs of transmembrane proteins are enriched in sites of various posttranslational modifications (PTMs), including phosphorylation, a crucial signal transduction-related PTM. Therefore, it is very likely that these MoRF- and PTM-enriched IDRs are involved in regulating protein activity, being capable of undergoing disorder-to-order transition at binding to specific binding partners in a PTM-dependent manner.³⁶ This is likely that the presence of MoRFs with PTM sites provides important means for fine tuning of the strength of disorder-based binding, through local structural changes caused by PTMs.³⁶ Furthermore, the presence of disordered regions is typically linked to the capability of proteins to interact with multiple partners, thereby defining their binding promiscuity and multifunctionality, phenomena linked to the protein structure-function continuum model.³⁷

In line with these considerations, published studies reported important roles of the C-terminal tails of rhodopsins in interaction with rhodopsin kinases,³⁸ targeting rhodopsins to specific cellular compartments, such as the outer segment,³⁹ regulation of the photoreceptor degeneration,⁴⁰ acting as key elements in membrane receptor activation, molecular recognition by signaling molecules, and receptor deactivation,⁴¹ playing vital role in





Fig. 2 Predicted intrinsic disorder content in the rhodopsins discussed in this article. (a) PONDR[®] VSL2-based³⁴ evaluation of the intrinsic disorder predispositions. Disorder score of 0.5 is taken as a threshold for intrinsic disorder, where residues/regions with disorder scores exceeding 0.5 are considered disordered (shown in red), whereas residues and regions with disorder scores ranging below 0.5 are considered as ordered (blue). (b) Length dependence of the PONDR[®] VSL2-predicted levels of intrinsic disorder in the rhodopsins discussed in this article. Disorder levels were evaluated as the percentage of predicted intrinsically disordered residues (PPIDR; *i.e.*, residues with a disorder score of ≥ 0.5) in a query protein. In both plots, rhodopsins are arranged from the least disordered (at the bottom of the plot) to the most disordered (at the top of the plot) in the following order: NsXeR from *Nanosalina* (UniProt ID: G0QG75); delta-rhodopsin (dR) from *Haloterrigena turkmenica* (UniProt ID: O93740); RmXeR from *Rubricoccus marinus* (UniProt ID: A0A259U1H3); KR2 from *Krokinobacter eikastus* (NCBI GenBank ID: BAN14808); NpHR from *Natronomonas pharaonis* (UniProt ID: P15647); MAC from *Leptosphaeria maculans* (UniProt ID: Q9HGT7); Arch3 from *Halorubrum sodomense* (UniProt ID: P96787); BR from *Halobacterium salinarum* (UniProt ID: P02945); ASR D217E from *Anabaena (Nostoc) sp. PCC7120* (UniProt ID: Q8YSC4); GtACR1 from *Guillardia theta* (UniProt ID: L1J207); ChR1 from *Chlamydomonas reinhardtii* (UniProt ID: Q93WP2); GtACR1 from *Guillardia theta* (UniProt ID: L1IFZ3); and ChR2 from *Chlamydomonas reinhardtii* (UniProt ID: Q8RUT8).

maintaining the structure of rhabdomeres, a specialized membrane-rich organelle that serve as a site of phototransduction, in *Drosophila*,⁴² and acts as a platform for interaction with various partners, such as arrestin.⁴³

It is clear that a better understanding of the multiple functional and regulatory roles of disordered regions of rhodopsins is necessary for the development of novel applications of these proteins in optogenetics. The lack of knowledge on disorder parts of rhodopsins does not allow us to provide an in-depth discussion of their biological roles and possible meaning for optogenetics. The only what we would like to do here is to pay attention on this fact and stress out that the studies of the disordered parts of rhodopsins are highly important.

Advantages of MR-based optogenetic approaches

Optogenetics offers a rapid and precise manipulation of single cells with light.^{4,23} This technology was mainly focused on plasma membrane expression of optogenetic tools in excitable cells and provided a methodological revolution in neuroscience.⁴⁴ The optogenetic approach shed light on the functions of certain neuronal populations in physiologic reactions,^{44–46} complex behavior^{47,48} and memory.^{3,49} The approach is also promising for control of cell physiology with light by selective expression of optogenetic tools in membranes of intracellular organelles.

Conventional experimental protocols and therapies for manipulation of organelles physiology are based on biochemical intervention, which have consequent drawbacks. The use of

chemicals is usually accompanied by diffusion of the substances in the cells and the body, which greatly affects the selectivity of targeting and the amount of the substance that reaches the targeted place. In addition, biochemical manipulations go along with a poor specificity and a limited exposure time. For example, mitochondrial uncouplers, like carbonyl cyanide *p*-trifluoromethoxyphenylhydrazone (FCCP) or 2,4-dinitrophenol (DNP), have a toxic effect and an off-target activity, since they reduce the plasma membrane potential and lysosomal acidity simultaneously with mitochondrial inner membrane potential.^{50,51} This side effect severely limits their use in research and clinics. The same is true for bafilomycin A1,^{52,53} chloroquine (CQ), or hydroxychloroquine (HCQ) – known inhibitors of autophagy. CQ and HCQ are FDA-approved candidates for clinical use, but they also have undesirable side cytotoxic effects.⁵⁴

Optogenetics allows selectively influencing cell compartments, certain cells, and even tissues, as well as selectively manipulating their activities with high time and spatial resolutions. Light induced activation of the cell allows for fast response that is reproducible upon repeated stimulation. The frequency of illumination is limited by the photocycle of the protein. If the illumination by short pulses can excite the majority of MRs, then it is possible to decrease the effective power of illumination and reduce a phototoxic damage.⁵⁵ Naturally, channelrhodopsins are the most convenient tools for rapid changing of plasma membrane potential in excitable cells.^{56,57} Using MRs with short photocycles allows modulating a membrane potential with frequencies of action potential generation in neurons.⁵⁸



Moreover, expanding the optogenetic toolkit provides researchers with complementary tools, which can be combined. For example, *CrChR2* (cation channel), which is activated by blue light, and *NpHR* (chloride pump), activated by orange light, were combined to activate and inhibit neural activity.^{59,60} This pair was also targeted to different subcompartments of retina ganglion cells: N-terminal fusion to ankyrin for soma localization and to postsynaptic density PSD-95-protein for dendrite localization.⁶¹ Recently, two other channelrhodopsins, the red-shifted cation-conducting ChrimsonR and the blue-light-absorbing chloride-conducting stGtACR2, were expressed in dopaminergic neurons of the ventral tegmental area in freely-moving mice, allowing bidirectional control of dopamine release, preference-avoidance, and social behavior.⁶²

Optogenetic experiments can be done with wide-field or patterned illumination of tissue. Two-photon excitation has been applied to achieve high spatial resolution and deeper tissue penetration.⁶³ Delivery of light to the tissue is often achieved by optical fiber, but the modern approach is to use implantable LED-devices.^{62,64,65} An important feature of optogenetics is the control of the frequency and time of light exposure, which could be adjusted for the photocycle of the chosen MR in certain surroundings.⁶⁶

Thus, organelle optogenetics combines the advantages of the optogenetic approach, including non-invasiveness, selectivity, temporal and spatial resolution, and reversibility of the effect with the specificity of organelle targeting.

Strategies of MR organelle targeting

Targeting of a foreign membrane protein – MR to a certain subcellular compartment is challenging. Despite this, a number of successful examples has been reported (Fig. 3). Plasma membrane targeting of MRs is under investigation since first optogenetic experiments. Fluorescent proteins are often fused to MRs for visualization of subcellular localization of the target. For bacteria and archaea-derived MRs, the addition of N-terminal part from eukaryotic MR at its N-terminus was combined with the addition of a membrane trafficking signal (TS) as well as the ER-export signal at the C-terminus (see detailed description in the section Plasma membrane MRs targeting). Nevertheless, some MRs of archaeal origin could be expressed in the plasma membrane only with TS at the C-terminus. In addition, these constructs comprise a self-cleavage peptide p2A after TS and before a fluorescent protein.

The mitochondrial inner membrane (IMM) targeting of MRs was successfully done by N-terminal fusion of MR to mitochondrial localization signal sequence (MLS) or a mitochondrial inner membrane resident protein part, containing MLS. For example, channelrhodopsin 2 (*CrChR2* from *Chlamydomonas reinhardtii*) was targeted to the IMM with four repeats of MLS of the 8th subunit of cytochrome *c* oxidase (COX8)⁷⁹ together with an N-terminal truncation of *Chr2*.³⁰ *CrChR2* with no deletions was also targeted to the IMM by long signal sequence of the ABC-transporter family protein (ABC10). For the outward

proton pump MAC from *Leptosphaeria maculans*²¹ IMM targeting a long N-terminal part, containing MLS, and a transmembrane helix of the IMM-resident protein mitofilin was used.⁷³

Lysosome targeting of the outward proton pump Arch3 was achieved by the chimeric construct called lyso-pHoenix. Arch3 together with fluorescent proteins was inserted between the 1st and the 2nd α -helices of tetraspanin CD63, which was responsible for lysosome localization. The similar construct (pHoenix) comprising a fragment containing Arch3 between the 3rd and the 4th helices of synaptophysin was used for synaptic vesicles targeting.⁶⁹ For endosome targeting MR ASR (D217E mutant) was fused to the C-terminal cytoplasmic sequence of chloride channel protein 5 (PhotonSABER).⁷⁷ Also vacuole targeting of proton pumps delta-rhodopsin (dR) from *Haloterrigena turkmenica* (via fusion to the amino acid transporter Avt6)⁸⁰ and rhodopsin from *Ustilago maydis* in *Saccharomyces cerevisiae* was reported recently.⁸¹

For endoplasmic reticulum targeting channelrhodopsin green receiver, ChRGR was fused C-terminally to two transmembrane helices of a mouse ryanodine receptor 2 and the fluorescent protein Venus.⁷⁷ A viral rhodopsin OLPVR1 was observed in the ER, although no signal sequence was added to the protein.⁷⁸

This was a brief overview of the signals for organelle targeting of MRs. Next, for each organelle we describe details of targeting and specific physiological effects observed in optogenetic experiments. Targeting strategies and optogenetic effects of MRs are summarized in Table 1 and specific signal sequences, used for targeting, are represented in Table S1 (ESI[†]).

Optogenetics of organelles

Plasma membrane: membrane potential and metabolic control

In order to better understand organelle optogenetics, we will first describe targeting and optogenetic effects of MRs expressed in the plasma membrane. Historically, plasma membrane was the first target for optogenetics, and plasma membrane-targeted tools are still the major MR-based optogenetic instruments.⁸⁸ In fact, plasma membrane-directed optogenetics remains to be the main area for which novel MR-based optogenetic tools are deeply studied and improved.⁵⁵ There are no reports on engineering MRs with novel properties for the use in intracellular compartments, which have not been used previously as optogenetic tools at the plasma membrane. MR-based optogenetics has demonstrated its significance for neuroscience.⁸⁹ In such cases, specific promoters are used to selectively express optogenetic tools in certain populations of neurons.^{79,90} Such approach allows neural circuit identification and is of vital importance for studies of brain functions.^{91–93} Optogenetics also provided a unique ability to manipulate complex behavior and memory in living animals.^{94,95}

Plasma membrane MRs targeting. In a number of cases successful plasma membrane targeting of MRs was reported.^{67,68,88} Several MRs, which are derived from eukaryotic hosts (like *CrChR1*,





Fig. 3 Overview of MR-based organelle optogenetic tools and targeting strategies. Outward proton pumps Arch3 and ArchT, from *Halorubrum sodomense* and *Halorubrum* strain TP009, respectively, and inward proton pumps NsXeR from *Nanosalina* sp. and RmXeR from *Rubricoccus marinus* were expressed in plasma membrane and used to control cytosol pH.^{67,68} Outward proton pump Arch3 and inward proton pump NsXeR were exploited for control of lysosomal pH.⁶⁹ Arch3 was also used for synaptic vesicles acidification.⁶⁹ Inward proton pump (ASR – anabena sensory rhodopsin mutant D217E) was used for endosome alkalization.⁷⁰ Channel rhodopsin ChR2 (from *Chlamydomonas reinhardtii*),^{71,72} and proton pumps MAC (from *Leptospaeria maculans*)^{73,74} and delta-rhodopsin (from *Haloterrigena turkmenica*)^{75,76} were expressed in inner mitochondrial membrane and triggered an optogenetic decrease or increase of the mitochondrial membrane potential respectively. The channelrhodopsin green receiver (ChrGR)⁷⁷ and type 1 viral channelrhodopsin OLPVR1 (Organic Lake phycodnavirus rhodopsin)⁷⁸ were expressed in the endoplasmic reticulum to induce Ca²⁺ release to the cytosol and cell contraction.

CrChR2 – channelrhodopsins 1 and 2 from *Chlamydomonas reinhardtii*, have their own N-terminal targeting signals and other internal signals that drive their plasma membrane targeting.⁶ MRs derived from prokaryotic (bacterial and archaeal) hosts usually do not have signals, which target them into eukaryotic cells.⁹⁶ For these proteins, a general strategy is the addition of signaling peptides derived from eukaryotic proteins or protein segments. The N-terminal signal peptide

serves for ER membrane insertion during protein synthesis.⁹⁷ Membrane trafficking signal (TS, for example from the potassium channel Kir2.1) as well as ER-export sequence (ER_{ex}, for example, FCYENEV, also from Kir2.1) are often added to the C-terminus of the protein.^{96,98} For visualization, fluorescent proteins (FPs, often GFP variants) are frequently fused to the C-terminus of a target protein. FP could be flanked by TS at the N-terminus and ER_{ex} at the C-terminus,⁶⁸ or have both signals



Table 1 Optogenetic control of cell physiology by targeted expression of MRs in membranes of the subcellular organelles

MR	Targeting strategy	Optogenetic effects on cell culture/organism	Ref.
Plasma membrane			
ArchT from <i>Halorubrum</i> sp. TP009	ArchT_BFP2_TS_ER _{ex} : TS – membrane trafficking signal BFP2 – blue fluorescent protein ER _{ex} – ER-export signal	Cytosol alkalization by 0.3 pH-units in retinal pigment epithelial cells. Activation of localized plasma membrane ruffling.	67
Arch3 from <i>Halorubrum sodomense</i>	Arch3_TS_eYFP_ER _{ex} : TS – membrane trafficking signal eYFP – enhanced yellow fluorescent protein ER _{ex} – ER-export signal	Cytosol alkalization by 1.1 pH-units in HeLa cells. Cell shrinking and apoptosis via a mitochondrial-mediated pathway. Reduction of chemotaxis of <i>C. elegans</i> (Arch3 expression in amphid sensory neurons).	68
RmXeR from <i>Rubricoccus marinus</i>	RmXeR_TS_eYFP_ER _{ex} : TS – membrane trafficking signal eYFP – enhanced yellow fluorescent protein ER _{ex} – ER-export signal	Cytosol acidification in an alkaline medium (pH 9.0). Reduction of cell shrinking and apoptosis.	68
Arch3 from <i>Halorubrum sodomense</i>	Arch3_TS_p2A_RFP: TS – membrane trafficking signal RFP – red fluorescent protein	Cytosol alkalization by 0.3 pH-units in HeLa cells under physiological conditions (in standard cell culture medium).	82
NsXeR from <i>Nanosalina</i> sp.	NsXeR_TS_p2A_RFP: TS – membrane trafficking signal RFP – red fluorescent protein	Cytosol acidification by 0.6 pH-units in HeLa cells under physiological conditions (in standard cell culture medium).	82
Mitochondrial inner membrane			
Mutants of Chr2 from <i>Chlamydomonas reinhardtii</i> (Chr2: I197S, C128A/H134R, C128S/D156A – SSFO, Tr)	mt/2mt/4mt-Chr2(mut)-YFP: mt – cytochrome <i>C</i> oxidase 8 presequence (first 32 a.a.), 2mt, 4mt – tandem repeats of mt, YFP – yellow fluorescent protein 4mt-Δ24Chr-YFP: Δ24Chr2 – deletion of the first 24 a.a	No significant localization in mitochondria. Mitochondrial localization in HEK293T, HeLa, GA-PLXR, human cardiomyocytes, pancreatic β-cells	71
Mutant of Chr2 from <i>Chlamydomonas reinhardtii</i> Chr2 (C128S/D156A – SSFO)	4mt-Δ24Chr2(SSFO)-YFP:	Mitochondrial localization in HEK293T, HeLa, GA-PLXR, human cardiomyocytes, pancreatic β-cells. Optogenetic stop of cardiomyocytes beating. Optogenetic decrease of glucose-bursted ATP production. Increased oxygen consumption in HeLa cells	72
Mutant of Chr2 from <i>Chlamydomonas reinhardtii</i> Chr2(H134R – GF)	mito-Chr2(GF)-eYFP: mito-ABCB10 presequence (first 140 a.a.), eYFP – enhanced yellow fluorescent protein	Mitochondrial localization in H9C2, HeLa, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Programmed cell death (apoptosis) of 80% of HeLa cells, triggered by acute illumination. Mitochondrial utilization by mitophagy, the preconditioning effect of low-intensity illumination.	
Mutant of Chr2 from <i>Chlamydomonas reinhardtii</i> Chr2(H134R – GF)	mito-GF-eYFP: mito – renal outer medullary (ROMK) presequence eYFP – enhanced yellow fluorescent protein	No mitochondrial localization.	83
BR from <i>Halobacterium salinarum</i>	COXIV-BR: COXIV – cytochrome <i>c</i> -oxidase subunit IV (COX4) presequence from <i>Saccharomyces cerevisiae</i> BR – bacterioopsin gene after presequence	Mitochondrial localization in yeast cells (<i>Schizosaccharomyces pombe</i>), operating status and orientation confirmed.	
BR from <i>Halobacterium salinarum</i>	ATP2-BR, RIP1-BR: ATP2 – β subunit of the F ₁ F ₀ -ATPase from <i>Schizosaccharomyces pombe</i> RIP1 – Fe/S RISC protein signal sequence	No significant localization in the mitochondria of yeast cells (<i>Schizosaccharomyces pombe</i>).	75
Delta-rhodopsin (dR) from <i>Haloterrigena turkmenica</i>	mito-dR-myc: mito – mitochondrial presequence of human cytochrome <i>c</i> oxidase subunit VIII (first 29a.a.) myc – human c-Myc proto-oncogene, epitope tag	Mitochondrial localization in SH-SY5Y and CHO-K1 cells. SH-SY5Y cells: cell survival upon inhibition of the electron transport chain, suppression of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced cell death. CHO-K1 cells: suppression of cell death induced by rotenone.	
Delta-rhodopsin (dR) from <i>Haloterrigena turkmenica</i>	mito-dR: mito – mitochondrial presequence of human cytochrome <i>c</i> oxidase subunit VIII (first 29a.a.)	Mitochondrial localization in <i>Drosophila</i> dCHCHD2 ^{-/-} cells confirmed, MMP increased, ATP synthesis restored, and ROS level reduced. No direct confirmation of orientation and pumping direction was reported. Optogenetic decrease of insoluble α-synuclein. In clusters of	84



Table 1 (continued)

MR	Targeting strategy	Optogenetic effects on cell culture/organism	Ref.
		dopaminergic neurons – decrease in neuron death, an improvement in locomotor activity.	
Mutant of delta-rhodopsin (dR) from <i>Haloterrigena turkmenica</i> (D104N/K225A)	mito-dR: mito – mitochondrial presequence of human cytochrome <i>c</i> oxidase subunit VIII (first 29a.a.)	<i>Drosophila</i> 's mitochondrial localization, non-functional dR mutant.	
MAC from <i>Leptosphaeria maculans</i>	mitofilin (187 a.a.)-MAC-eGFP mitofilin – inner mitochondrial membrane protein eGFP – enhanced green fluorescent protein	Mitochondrial localization in <i>Caenorhabditis elegans</i> , MMP generation, matrix alkalization, and ATP synthesis in mitochondrial suspension. Increased resistance to mitochondrial toxins. Reversal of the protective effect of hypoxic preconditioning.	85
MAC from <i>Leptosphaeria maculans</i>	mitofilin(187 a.a.)-MAC-eGFP	Lifespan extension of <i>C. elegans</i> , reduction of age-associated physiological functional decline.	86
MAC from <i>Leptosphaeria maculans</i>	mitofilin(187 a.a.)-MAC-eGFP	Mitochondrial localization in mouse and human CD8+ T cells, increase in the mitochondrial membrane potential, increase in the mass of mitochondria, and improvement of migration and effector functions of CD8+ T cells.	74
Lysosomes and endosomes Arch3 from <i>Halorubrum sodomense</i>	CD63-pHluorin-Arch3-mKate-βHK-CD63 (pHoenix) CD63 – lysosomal membrane glycoprotein pHluorin – pH-sensitive green fluorescent protein mKate – far-red fluorescent protein βHK – transmembrane helix of the rat gastric H+/K+ ATPase β-subunit	Lysosomal localization in HEK293, HeLa. Light-driven acidification of lysosomes, alkalinized by bafilomycin A1.	69
ASR D217E – anabaena sensory rhodopsin from <i>Anabaena (Nostoc)</i> sp. PCC7120 mutant with an inward proton pump activity	ASR(D217E)-CIC5 (PhotonSABER) CIC5 – C-terminal cytoplasmic region of chloride channel protein 5	Early and late endosomal localization in hippocampal neurons, Purkinje cells. Light-dependent endosomal alkalization and inhibition of AMPA receptor endocytosis and motor learning in Purkinje cells <i>in vivo</i> .	70
Synaptic vesicles Arch3 from <i>Halorubrum sodomense</i>	Synaptophysin-pHluorin-Arch3-mKate-βHK-Synaptophysin (pHoenix) Synaptophysin – vesicular protein pHluorin – pH-sensitive green fluorescent protein mKate – far-red fluorescent protein βHK – transmembrane helix of the rat gastric H+/K+ ATPase β-subunit	Localization in synaptic vesicles of mouse hippocampal neurons and in organotypic brain slices. Light-driven acidification of synaptic vesicles, alkalinized by bafilomycin A1, increased vesicular transmitter accumulation.	69
Arch3 from <i>Halorubrum sodomense</i>	Synaptophysin-pHluorin-Arch3-mKate-βHK-Synaptophysin (pHoenix)	Localization of the pHoenix in mouse hippocampal or striatal neuron. They showed that proton efflux from GABAergic SVs is initially faster than glutamatergic SVs in intact synapses. Comparison of the filling rate of empty synaptic vesicles with glutamate and GABA.	87
Endoplasmic reticulum ChRGR channelrhodopsin-green receiver, engineered ChR1 from <i>Chlamydomonas reinhardtii</i>	ChRGR-ER-signal-Venus (ChRGR _{ER} -Venus): ER-signal – two transmembrane helices (Gln4765-Ile4866) of mouse ryanodine receptor 2 Venus – an improved variant of enhanced yellow fluorescent protein	An increase of cytosol Ca ²⁺ in the C2C12 cells. Induction of calcium-induced calcium release (CICR) and store-operated Ca ²⁺ entry (SOCE).	77
OLPVR1 from Organic Lake phycodnavirus	OLPVR1-GFP	Activation of Ca ²⁺ release from intracellular stores, activation of muscle contraction, tail flicking and swimming in <i>Xenopus laevis</i> tadpoles.	78

(TM and ER_{ex}) attached to the C-terminus.⁶⁷ This approach leads to efficient plasma membrane localization for a number of MRs. The most efficient plasma membrane localization for the chloride pump halorhodopsin from *Natronomonas*

pharaonis was achieved by the N-terminal addition of signal peptide from the β subunit of the nicotinic acetylcholine receptor (SP_{nAChR}) as well as TS and ER_{ex} at C-terminus (eNpHR3.0).^{88,96} For sodium pump KR2 from *Krokinobacter*



eikastus, the addition of the N-terminal chimeric signal from CrChR1 and CrChR2 and TS and ER_{ex} flanking the C-terminal FP gradually increased PM localization (eKR2).⁹⁸ Interestingly, for several proton-pumping MRs: bacteriorhodopsin from *Halobacterium salinarum*,⁸⁸ ArchT from *Halorubrum* strain TP009⁶⁷ (Fig. 4a), Arch3 from *Halorubrum sodomense*,⁶⁸ and xenorhodopsin from *Rubricoccus marinas* (RmXeR)⁶⁸ (Fig. 4b) only the addition of C-terminal TS and ER_{ex} leads to efficient PM localization. A general strategy was developed to improve plasma membrane expression of non-eukaryotic rhodopsins in mammalian cells, which proposes the stepwise addition of signal sequences.⁸⁸ However, for several proteins, for example outward and inward proton pumps Arch3 and NsXeR, successful plasma membrane targeting was achieved when TS was added to the C-terminus of the MR and FP was cleaved by the addition of p2A self-cleavage peptide (Fig. 4c).⁹⁹

Optogenetic control of plasma membrane electric potential.

Currently, the major physiological parameter controlled by the “classical” optogenetics is the membrane potential of excitable cells.¹⁰⁰ For this application, a vast variety of depolarizing and hyperpolarizing tools were proposed.⁵ Major depolarizing tools are cation channelrhodopsins, especially CrChR2 (and its modifications),¹⁰¹ and inward proton pumps (xenorhodopsins),⁹⁹ while major hyperpolarizing tools are halorhodopsins (inward Cl⁻ pumps) (NpHR from *Natronomonas pharaonis*),⁹⁶ outward sodium pump (KR2 from *Krokinobacter eikastus*),^{98,102} and outward proton pumps (Arch3 from *Halorubrum sodomense*¹⁰³ and MAC from *Leptosphaeria maculans*^{21,104}). Anion channelrhodopsins’ (AChRs: wild type GtACR from *Guillardia theta*¹⁰⁵ and engineered¹⁰⁶) effect on the membrane potential of excitable

cells depends on the chloride ion concentration and the subsequent reversal potential. Recently, potassium channelrhodopsins were found and proposed for neuronal inhibition.¹⁰⁷ An optogenetic control of the contractile activity of muscle cells was also achieved by plasma membrane expressed channelrhodopsins.^{108,109}

Optogenetic control of cytosol pH in non-excitable cells. The electrical activity of cells is not the only parameter that could be controlled by plasma membrane-targeted optogenetic tools – the pH value of the cytoplasm can be adjusted as well. Recently, robust and long (duration of minutes) cytosol alkalization (0.3 pH units) was demonstrated by ArchT activation in the plasma membrane of retinal pigment epithelial cells (Fig. 4a).⁶⁷ This process was accompanied by localized plasma membrane ruffling responses in the illuminated area (in NIH-3T3 mouse embryo fibroblasts). One work demonstrated even a higher amplitude of Arch3-mediated cytosol alkalization (1.1 pH units for HeLa cells in a neutral medium) as well as cytosol acidification by *Rubricoccus marinas* xenorhodopsin in an alkaline (pH 9.0) medium (Fig. 4b).⁶⁸ Arch3-mediated cytosol alkalization led to cell shrinking and apoptosis *via* a mitochondrial-mediated pathway. Furthermore, Arch-3 expression in amphid sensory neurons of *C. elegans* reduced chemotaxis after illumination.⁶⁸ Recently, optogenetic acidification of the cytosol by 0.6 pH-units in HeLa cells was achieved by expression of the inward proton pump NsXeR from *Nanosalina* sp. in the plasma membrane (Fig. 4c).⁸² While NsXeR is active under a wide pH-range, NsXeR-mediated acidification was performed under physiological conditions (in a standard cell culture medium).⁹⁹ Arch3-mediated alkalization (by 0.3 pH-units) was



Fig. 4 Cytosolic pH manipulation by plasma membrane expression of outward and inward MR proton pumps. Light activation of the outward proton pump ArchT (a) or Arch3 (b) (outward pump from *Halorubrum* strain TP009 and *Halorubrum sodomense*, respectively) in the plasma membrane leads to cytosol alkalization in the neutral medium.^{67,68} Activation of RmXeR (inward pump from *Rubricoccus marinas*) (b) in the plasma membrane leads to a decrease in cytosol pH in an alkaline (pH 9.0) medium.⁶⁸ Activation of Arch3 and NsXeR (inward pump from *Nanosalina* sp.) (c) in the plasma membrane leads to subsequent cytosol alkalization and acidification in a neutral medium.⁵⁶



also reported, showing the usefulness of the Arch3 optogenetics, as originally introduced in previous studies.⁸²

The pH value of the cytoplasm (pH 7.2) and extracellular fluid (pH 7.4) is a fundamental parameter for homeostasis. In cancer cells, the cytosol is constantly alkalized (pH higher than 7.4), which is coupled to acidification of extracellular space (pH lower than 7.1). Higher intracellular pH alters cell phenotype and gene expression profile. For example, cyclin D1 expression is activated by cytosol alkalization.¹¹⁰ An increased intracellular pH may promote cancer cell migration during metastasis,¹¹¹ likely due to the higher cofilin activity.¹¹² Also, an increased intracellular pH activates WNT-signaling in cells during embryogenesis in vertebrates.¹¹³ Expression of inward and outward proton pumps in the plasma membrane may open new opportunities in optogenetic cytosol pH manipulation and control of cell physiology.

Mitochondria: optogenetic control of mitochondrial membrane potential

Mitochondria are double-membraned cellular organelles, mainly serving the energy needs of the cell. They are vital cellular compartments, especially for nerve¹¹⁴ and muscle¹¹⁵ tissues, where energy consumption is high. Certain mitochondrial dysfunctions can lead to deafness, blindness, dementia, diabetes, and cardiomyopathy¹¹⁶ and are involved in cancerogenesis,¹¹⁷ neurodegeneration,¹¹⁸ and aging.¹¹⁹ The state of the mitochondria largely determines the physiology of the cell. The efficiency of mitochondria depends on the mitochondrial membrane potential (MMP) of the IMM.¹²⁰ This is an important factor that controls the synthesis of ATP, generation of reactive oxygen species (ROS),¹²¹ and the functionality of the transport of immature proteins through the IMM.¹²² Another important and strictly controlled parameter is the concentration of calcium ions in the mitochondria.¹²³ Calcium acts as a signaling molecule and is involved in many important interactions between the mitochondria and the cell, determining the cell's fate.^{124,125}

Mitochondrial protein import. Mitochondria are organelles of endosymbiotic origin, and despite the fact that mitochondria can perform protein synthesis,¹²⁶ most mitochondrial proteins are encoded in the nuclear genome, since the mitochondrial genes mainly migrated to the nucleus.¹²⁷ Synthesis of the corresponding proteins occurs in the cytosol on free ribosomes due to the absence of ER signals, and then the protein precursor is imported into the mitochondrial compartments.^{128,129} Delivery and sorting of the proteins to mitochondria is carried out using mainly various N-terminal signals, as well as internal or C-terminal signal sequences.¹³⁰

During translation of mitochondrial proteins encoded in the nuclear DNA, N-terminal amino acids often have a signal sequence which directs the protein into the mitochondrion. Most proteins pass through the TOM40 complex of the outer membrane (OM) of mitochondria. Proteins of this complex recognize the signal peptide, recruit it, and send it to the pore of the main subunit of the complex. Transported proteins then may follow several pathways, depending on their signal

sequences. If the N-terminal signal is an amphipathic alpha helix, it is recognized by the TIM23 protein complex in the IMM. The charge helps the helix to pass through the membrane, where, on the matrix side, the translocated protein is recruited by an ATP-driven chaperone (mtHsp70), which pulls out the protein from the pore of the TIM23 complex.¹³¹ Then, the signal sequence is cleaved by MPP protease in the matrix. If a protein has internal hydrophobic signals, the translocation can be stopped and the protein is laterally released into the IMM.¹²⁸ If there is no such signal, then the protein will be completely released into the matrix, where it will be picked up by chaperones if required. Then, in the case of a membrane protein, it is targeted into the IMM from the matrix by OXA1, which inserts proteins from both genetic origins (mitochondrial and nuclear).¹³²

Mitochondrial targeting of MRs. Optogenetic influence on the physiology of mitochondria can be achieved by targeted expression of MRs in mitochondria. This is usually done by attaching signal sequences from mitochondrial proteins to a selected MR.⁷¹⁻⁷³ However, there are no unambiguous approaches for targeting of a specific protein. There is no assurance that a signal that has been effectively used in one instance will be appropriate for other proteins. Nevertheless, there are several described combinations that work efficiently.¹³³

Bacteriorhodopsin (BR) was targeted to IMM in yeast cells by using the cytochrome *c*-oxidase subunit IV (COX4) signal sequence. This presequence is 22 residue-long and has a cleavage site after the 17th amino acid residue (a.a.).¹³⁴ However, the attempts to do the same with signal sequences of the β subunit of F_1/F_0 -ATPase and Fe/S Rieske protein were unsuccessful.⁸³

CrChR2 mutants were successfully targeted to the inner membrane of mitochondria using a 4-fold tandem repeats of the signal of a mitochondrial inner membrane protein, the 8th subunit of cytochrome *c* oxidase (COX8, first 32 a.a.)¹³⁵ with a deletion of the first 24 amino acids of ChR2 (Fig. 5a).⁷¹ Also, ChR2 mutants were expressed in the IMM with an unusually long (140 a.a.) signal sequence of the ABC-transporter family protein (ABC10).⁷² The first 105 a.a. of this sequence are cleaved in the mitochondria.¹³⁶ COX8 signal sequences with less than 4 repeats and no protein changes, as well as the signal sequence of ROMK, mitochondrial KATP channel signal sequences, failed to show the required level of localization.⁷² Also, delta-rhodopsin (dR) and non-functional dR mutant (D104N/K225A) were expressed with COX8 signal sequence (first 29 a.a.).^{75,76}

Proton pump MAC in the latest studies^{73,74,86} was expressed in mitochondria of *C. elegans* and mouse T-lymphocytes by N-terminal fusion to the first 187 a.a. of the IMM-resident protein mitofilin (Fig. 5b). This protein has a 34 a.a.-long cleavable signal peptide and the transmembrane part, which appears to remain with the delivered protein.¹³⁷

Mitochondrial uncoupling using MRs. One of the obvious candidates for controlling mitochondria physiology is ion channels, especially those which have high proton conductance. Natively, mitochondria have their own stable potential.¹²⁰ Its dissipation makes it possible to simulate pathological





Fig. 5 Schematic representation of mitochondria optogenetic approaches. Channelrhodopsin 2 (*CrChR2* from *Chlamydomonas reinhardtii*) was targeted to IMM for optogenetic mitochondrial uncoupling (a).^{71,72} Proton pump MAC (from *Leptosphaeria maculans*) (b) was applied for optogenetic increase of MMP.^{73,74,86}

conditions,¹³⁸ bringing mitochondria into a state of increased respiration,⁸⁵ and affecting calcium homeostasis.¹³⁹

First optogenetic tools for mitochondria control were channelrhodopsin 2 mutants (*CrChR2*: I197S, C128A/H134R, C128S/D156A – SSFO) (Fig. 5a).⁷¹ *CrChR2* and its mutants were targeted to the IMM in HEK293T and HeLa cells, human cardiomyocytes, and melanoma cells (GA-PLXR). The localization and correct orientation in the IMM were confirmed, as well as the functioning of the protein. Activation of the SSFO mutant of *CrChR2* was carried out by 495 ± 5 nm blue LED (2 mW mm^{-2}), and the closing of the channel was induced by 595 nm LED (12 mW mm^{-2}). *CrChR2*-mediated drop in MMP led to reduced mitochondrial calcium influx after histamine stimulation in HeLa cells. It also temporarily stopped the beating of cardiomyocytes. Also, a decrease of ATP production in pancreatic β -cells and increased oxygen consumption in HeLa cells were observed during optogenetic activation of *CrChR2* in the IMM.

Another mutant *CrChR2*(H134R-GF) was used to trigger autophagy and apoptosis by light.⁷² Depending on the degree of IMM optogenetic decoupling, the effect can be exactly the opposite. Acute illumination (475 nm LED, 5 mW mm^{-2} , 24 h) triggered the programmed cell death of 80% of HeLa cells, which was predominantly realized by the apoptotic pathway. However, low intensity illumination (0.2 mW mm^{-2} , 2 h) induced mitophagy and mediated a preconditioning effect: cell viability after acute illumination was two-fold higher in a preconditioned group compared to control cells.

Energizing mitochondria with MR-proton pumps. Using the expression of proton pumps in the IMM, it is possible to restore a functionally significant membrane potential of mitochondria in the case of its partial loss. MAC-rhodopsin was expressed in the IMM.⁷³ Optogenetic activation of MAC in mitochondria

leads to MMP generation, matrix alkalization, and ATP synthesis without succinate in the mitochondrial suspension (Fig. 5b). Additionally, activation of MAC increases *C. elegans* resistance to mitochondrial toxins and affected AMPK-mediated energy deficit signals. At the same time, in modified *C. elegans*, optogenetic MMP generation during hypoxic preconditioning reversed the protective effect of preconditioning on hypoxia/reoxygenation damage. Later, this optogenetic tool was implemented in order to prolong the lifespan of *C. elegans*. It was shown that optogenetic MMP generation in adult worms prolongs the lifespan as well as reduces age-associated physiological functional decline.⁸⁶ Another elegant implementation of MAC was its expression in the mitochondria of T-lymphocytes. It was shown that photoactivation of MAC increases the MMP and mitochondrial mass and improves mitochondrial function in mouse and human CD8+ T cells.⁷⁴ The migration of these cells was greatly accelerated, and the ability of the cells to kill tumor cells was improved.

Another proton pump – dR was expressed in mitochondria of CHO-K1 and SH-SY5Y cells. Mitochondrial localization was confirmed and optogenetic reduction of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death was demonstrated.⁷⁵ Nevertheless, the direction of proton pumping by dR was not shown, and the direct confirmation of MMP increase in cell culture was not made. Later, dR was expressed in *Drosophila* mitochondria.⁷⁶ The CHCHD2 (dCHCHD2) knockout flies (a model of Parkinson's disease) with the mitochondrial dR were subjected to prolonged illumination. The MMP and ATP synthesis were restored. Maintaining the functional potential bypassing the electron transport chain reduces the formation of ROS both directly and by normalizing calcium concentration. As a result, there was an increase of mitochondrial calcium accumulation in dopaminergic



neurons of *dCHCHD2*^{-/-} flies and a decrease in the number of insoluble inclusions of overexpressed α -synuclein in neurons. In addition, the expression of dR in dopaminergic neurons showed an optogenetic decrease in neuronal death, as well as an improvement in locomotor activity in flies expressing dR in comparison with the non-functional mutant.

Taken together, two types of mitochondrial optogenetic tools were proposed: *CrChR2* to optogenetically reduce MMP and proton pumps MAC and dR to increase MMP. A variety of physiological outcomes can be controlled by light using these tools from ATP synthesis and mitophagy up to the whole-organism lifespan.

Lysosomes and endosomes: optogenetic control of pH and proteolysis

Lysosomes are small single-membrane organelles containing a number of enzymes that can break down macromolecules.^{140–143} For the proper physiological function of lysosomes, it is essential to accumulate protons within the lumen in order to maintain an optimal acidic pH (4.5–5.0) for enzyme function. This is achieved by a proton pump vesicular proton ATPase (V-ATPase) under the assistance of other transporters and channels that regulate ion concentrations in lysosomes.¹⁴⁴ Dysregulation of acidification leads to the changes in intraluminal pH, which can result in lysosomal storage diseases and is associated with Alzheimer's disease, Parkinson's disease, and some others.^{145,146} Recently, the participation of lysosomes in many intracellular signaling and metabolic pathways was demonstrated.¹⁴⁷ Involvement of altered lysosome function in the pathogenesis of metabolic disorders¹⁴⁸ and cancer^{149,150} was also found.

Lysosomes and endosome protein targeting. Lysosomes contain a significant amount of membrane proteins. Delivery and sorting of proteins into lysosomes are guided by signal sequences. Lysosomal and endosomal membranes contain lysosomal-associated (LAMPs) or lysosomal integral membrane proteins (LIMPs).¹⁵¹ The well-known transmembrane proteins are LAMP-1 and LAMP-2,¹⁵² which are the main components of the lysosomal membrane, as well as LIMP-2¹⁵³ and the tetraspanin CD63.¹⁵⁴ The transport of newly synthesized LAMPs and LIMPs from the *trans*-Golgi network (TGN) to lysosomes and endosomes is carried out in two ways: directly from TGN to endosomes, and then to lysosomes, or from TGN first to the cell surface, then through endocytosis to endosomes, and, finally, to lysosomes.¹⁵⁵ Traditional signals of targeting proteins to lysosomes are tyrosine or dileucine-based motifs located on the cytosolic side of lysosomal transmembrane proteins.¹⁵⁶ Such motifs interact with complexes of heterotetrameric adapter proteins AP1, AP2, AP3, or AP4, which are capable of recruiting coat proteins (*e.g.* clathrin)¹⁵⁷ and initiating the assembly and formation of coated vesicles.¹⁵¹ Several transmembrane proteins require multiple motifs for targeting into lysosomal membranes.^{158,159}

Membrane dynamics, which affects the degradation and recycling of proteins within cells, plays a critical role in maintaining homeostasis.¹⁶⁰ Endosomes are a dynamic system that undergoes morphological and biochemical changes associated

with the transport of vesicles.¹⁶¹ Among endosomes, two pools are distinguished: early and late endosomes. Early endosomes are small vesicles that emerge from clathrin-coated pits derived from the plasma membrane.^{162,163} Early endosomes have a slightly acidic intraluminal pH of about 6.2–6.3.¹⁶⁴ One of the best-studied proteins associated with early endosomes is Rab5. Early endosomes must then turn into late endosomes, which is accompanied by a change in Rab5 to Rab7.¹⁶⁵ The transition to late endosomes is also accompanied by acidification of the internal lumen of endosomes up to 5.0–5.5.¹⁶⁴ Some late endosomes may have a complex internal vesicular structure and are also referred to as multivesicular bodies (MVB).¹⁶⁶ Finally, late endosomes fuse with lysosomes to degrade intravesicular cargo.¹⁶⁷ Defects in the endocytic pathway are primary reason of storage diseases^{168,169} as well as are associated with many pathological conditions such as cancer and neurodegenerative diseases.^{170,171} Regulation of endocytic and secretory pathways is important, for example, for neurons to ensure normal synapse function.¹⁷²

MRs lysosome and endosome targeting. Expression of an outward proton pump Arch3 in lysosomes was achieved by the insertion of Arch3 in a chimeric construct called lyso-pHoenix (Fig. 6a).⁶⁸ Arch3 was flanked by superecliptic-pHluorin at N-terminus and mKate at C-terminus and this fragment was inserted between the 1st and the 2nd α -helices of tetraspanin CD63. To achieve a correct topology of CD63, a transmembrane helix from β HK (rat gastric H⁺/K⁺-ATPase, β -subunit) was added after mKate. In the lyso-pHoenix construct the N-terminus of Arch3 is oriented inside lysosomes, ensuring pumping of protons into the lumen of the lysosome. Also, a superecliptic-pHluorin (sepHluo) is exposed to the lysosome lumen, which enables lysosome pH measurement, and mKate is exposed to the cytoplasm. sepHluo together with mKate allows ratiometric imaging of lysosome pH. The same chimeric construct was used to target another MR – inward proton pump *NsXeR* to lysosomes (Fig. 6b).¹⁷³

In another study, Kakegawa *et al.*⁷⁰ targeted Anabena Sensory Rhodopsin mutant (ASR D217E) which acts as an inward proton pump to endosomes, the construct was called PhotonSABER (Fig. 6c). To target ASR to early endosomes, it was fused to the C-terminal cytoplasmic sequence of chloride channel protein 5 (ClC5). ClC5 has been shown to localize predominantly in early endosomes.¹⁷⁴ However, immunocytochemical staining showed that this tool is expressed in early and late endosomes simultaneously.

Optogenetic control of lysosome and endosome pH. Acidification of lysosomes with the lyso-pHoenix was shown for HEK293 with lysosomes alkalized with bafilomycin A1. Lysosomal pH rapidly dropped during illumination and recovered after the termination of illumination (Fig. 6a). Fast recovery kinetics indicated intense proton leakage from the lysosomes, likely mediated by proton exchangers.^{175–178}

Alkalinization of lysosomes was performed by inward proton pump *NsXeR* (Fig. 6b). The effectiveness of this Lyso-*NsXeR* optogenetic approach was demonstrated through its ability to inhibit the activity of lysosome proteolytic enzymes.¹⁷³






Fig. 6 Schematic representation of lysosome- and endosome-based optogenetic approaches. Three types of optogenetic tools were targeted to lytic compartments: outward proton pump Arch3 (from *Halorubrum sodomense*) for lysosomes acidification (a),⁶⁹ inward proton pump NsXeR (from *Nanosalina* sp.) for lysosomes alkalization (b)⁷⁰ and inward proton pump ASR (Anabena Sensory Rhodopsin mutant D217E) (PhotonSABER) for endosomes alkalization (c).¹⁷³

For PhotonSABER, it was demonstrated that light-dependent endosomal alkalization inhibits endocytosis of the AMPA-type glutamate receptor; the latter, in turn, blocks long-term depression in parallel fibers of Purkinje cells synapses (PF-LTD) (Fig. 6c).⁷⁰ This tool was used to study learning and memory. Unfortunately, PhotonSABER is not selective for endosome subcompartments targeting and therefore requires further development and optimization.

Optogenetic acidification or alkalization of lysosomes and endosomes is a promising way for metabolic control in living cells. Due to the fact that lysosomes and endosomes are relatively small compartments, with a large surface/volume ratio, dramatic changes in luminal pH could be achieved by activation of rhodopsin-proton pumps (more than 1 pH unit). Therefore, the concept of using optogenetic tools to control pH for various types of endosomes and lysosomes is an important and relevant task.

Synaptic vesicles: optogenetic control of neurotransmission

Optogenetic control of neurotransmission was recently demonstrated.⁶⁹ In neurons, neurotransmitter molecules are stored in and released to the synaptic cleft by synaptic vesicles (SVs). Neurotransmitters interact with a certain receptor on the postsynaptic membrane, leading to excitatory or inhibitory postsynaptic potentials, allowing the transmission of signals between neurons. SVs are small membranous vesicles filled

with neurotransmitters.¹⁷⁹ The loading of neurotransmitters into SVs is critically dependent on the activity of the V-ATPase, which provides an acidic environment by pumping protons into the lumen of the vesicles, allowing the transporters to load them with neurotransmitters.^{180,181}

Synaptic vesicle protein targeting. The major essential functions of SVs are performed by a set of integral membrane proteins and membrane-associated proteins that can attach and detach during the vesicular cycle. Well-known SV proteins are, for example, synaptophysin (Syp), synaptobrevin (Syb), synaptotagmins (Syts), and syntaxins (Syxs) which are part of the vesicular (v-) complex of SNARE proteins, and others.^{182,183} These proteins may be associated with neurotransmitter loading or release, SV exocytosis–endocytosis mechanisms, and synaptic ion homeostasis. Most of them were identified using mass spectrometric analysis.^{183–185} However, despite the diverse synaptic proteome, many functionally important SV proteins and their isoforms remain unknown.^{186–188} Mechanisms of SV protein targeting and consequent signal sequences are still under discussion, and detailed mechanisms are described only for a few of them. For example, it was shown that synaptotagmin I has a cluster of acidic a.a. EEEVD and a dileucine-like motif ML at its C-terminus which mediates sorting from endosomes to SVs.^{189,190}

Targeting MRs to SVs was done by inserting Arch3 proton pump between the 3rd and the 4th helix of tetraspanin–synaptophysin.¹⁹¹



The chimeric construct was similar to lyso-pHoenix except substitution of CD63 to synaptophysin.⁶⁹

Optogenetics of synaptic vesicles. Using the pHoenix construct, it was possible to functionally replace the activity of the pre-inhibited V-ATPase proton pump in SVs of neurons. Activation of the pHoenix by light allowed SVs to be rapidly acidified, creating a proton-driven force for efficient neurotransmitter accumulation. Repeated optogenetic stimulation of pHoenix showed acidification of the vesicles which proves the reversibility of these processes. Optogenetic control of neurotransmission may be considered as a complementary approach to classical optogenetic control of neurons.

Endoplasmic reticulum: optogenetic control of calcium signaling

Endoplasmic reticulum (ER) is a membrane system that plays a vital role in protein synthesis, sorting, and folding. Translation of proteins of the secretory pathway begins when mRNA connects to the ribosome. Emerging proteins are transported to the ER through the interaction of the N-terminal signal sequence and the signal recognition particle (SRP). The SRP complex contacts the SRP receptor, the ER resident membrane protein. Later translation continues in ER and the polypeptide can co-translationally enter the ER lumen through the translocon, a channel containing Sec proteins.¹⁹² Besides co-translational translocation described above, there is also a post-translational translocation when proteins are transported after the completion of their synthesis.¹⁹³ ER is also responsible for the synthesis and transport of lipids, and the accumulation of Ca²⁺ and its regulated release into the cytosol.¹⁹⁴ Intracellular Ca²⁺ is a major secondary messenger in the cell, and optogenetic control of ER Ca²⁺-release is a new promising approach that allows controlling calcium signaling cascades and processes which depend on calcium concentration (myogenesis, muscle contraction, neurons excitation and morphology).

MRs endoplasmic reticulum targeting. T. Asano *et al.*¹⁹⁵ developed a strategy for targeting MR to ER. Ryanodine receptor 2 (RYR2) is located predominately in the sarcoplasmic reticulum (SR, found in muscle cells) of cardiomyocytes and is responsible for calcium-induced calcium release from SR providing heart muscle contraction.¹⁹⁶ For optogenetic manipulation of ER Ca²⁺ stores a photosensitive cation channel (channelrhodopsin-green receiver, ChRGR¹⁹⁷), which is permeable to calcium, was targeted in the ER/SR of mouse skeletal myoblast cells.⁷⁷ In order to target MR in the ER, two transmembrane helices (Gln⁴⁷⁶⁵-Ile⁴⁸⁶⁶) of mouse RYR2 were inserted in-frame between ChRGR and Venus (ChRGR_{ER}) (Fig. 7a). The signal from ChRGR_{ER}-Venus was confined in the perinuclear region in contrast to the conventional ChRGR-Venus, which localized in the plasma membrane with the original membrane targeting property.

The general strategy of MRs targeting to subcellular organelles is the addition of the proper signal sequences. However, sometimes no signal sequence is needed to achieve ER targeting. Thus, A.-S. Eria-Oliveira *et al.*⁷⁸ demonstrated that type 1 viral channelrhodopsin OLPVR1 (Organic Lake phycodnavirus

rhodopsin, construct OLPVR1-GFP) localizes intracellularly in the ER in HEK293T cells (Fig. 7b).

Optogenetic control of cytosol Ca²⁺ by ChRGR in the ER. In 2018, T. Asano *et al.*⁷⁷ for the first time demonstrated the control of intracellular Ca²⁺ dynamics using light and targeting a photosensitive cation channel permeable to calcium ions in the ER/SR. This channel was channelrhodopsin-green receiver, ChRGR¹⁹⁷ – chimeric protein CrChR1 (channelrhodopsin-1 from *Chlamydomonas reinhardtii*) with the sixth helix domain from CrChR2 (channelrhodopsin-2 from *Chlamydomonas reinhardtii*). In order to confirm the functionality of ChRGR_{ER} in the ER/SR, a red fluorescent Ca²⁺ indicator R-CaMP1.07 was used. ChRGR_{ER} was expressed in mouse skeletal myoblasts (C2C12) and optical stimulation caused: (1) the increase of fluorometric Ca²⁺ regardless of extracellular concentration of Ca²⁺ and (2) the store-operated Ca²⁺ entry (SOCE) (Fig. 7a).

Optogenetic control of cytosol Ca²⁺ by OLPVR1 in the ER. Recently, it was shown that the viral rhodopsin OLPVR1 (OLPVR1-GFP) when expressed in *Xenopus* oocytes and HEK293T localizes in the ER.⁷⁸ Light activation of this rhodopsin caused a rise in intracellular Ca²⁺ through release from IP3-dependent Ca²⁺ stores (Fig. 7b). Moreover, *in vivo* experiments showed that a light-induced calcium increase triggers tadpoles muscle contraction and subsequent motion.⁷⁸

In summary, it is possible to manipulate the Ca²⁺ release from intracellular stores such as ER/SR using optical stimulation. The organelle optogenetic approach would make it possible to understand the importance of intracellular calcium dynamics with unprecedented spatiotemporal precision in various cells. Optical regulation of internal calcium signaling cascades, initiated by a calcium-induced calcium release or the store-operated Ca²⁺ entry, is a promising idea for the nearest future.

Challenges of MR-based optogenetic approaches

In order to plan and optimize an optogenetic experiment, one must be aware of possible problems and “side effects”. One of the major challenges in organelle optogenetics is the organelle targeting efficiency of chosen optogenetic tools. MRs directed to any cell compartment require an efficient signal sequence or fusion to an organelle resident protein or its part. Though recently native organelle-targeting motifs were predicted in a variety of rhodopsins.¹⁹⁸ There is still no universal strategy for organelle targeting, though a large number of signal sequences have been described, such as those targeting the plasma membrane or the mitochondrial matrix. However, problems could occur due to the complexity of the protein targeting process. In accordance with current knowledge, the use of a particular approach is determined not only by the signal sequence, but also by the protein itself, its length, charge, and hydrophobicity of its regions, *etc.*¹²⁸ For example, the N-terminal signal sequence from COX8 has been widely used to target proteins to the mitochondrial matrix.¹⁹⁹ Interestingly, the N-terminal addition of one, two, or three repeats of the COX8 signal sequence was not sufficient to target ChR2 to IMM.^{71,72} It has been confirmed that the use of four repeats of





Fig. 7 Optogenetics of ER. Activation of ChRGR in the ER of mouse skeletal myoblast cells triggers ER-calcium release (measured by R-CaMP1.07) (a).¹⁹⁵ ChRGR – chimeric protein CrChR1 (channelrhodopsin-1 from *Chlamydomonas reinhardtii*) with the sixth helix domain from CrChR2 (channelrhodopsin-2 from *Chlamydomonas reinhardtii*).¹³⁸ Activation of ER-expressed OLPVR1 (Organic Lake phycodnavirus rhodopsin 1) leads to a rise of intracellular Ca^{2+} by a release from IP₃-dependent Ca^{2+} stores. Subsequent activation of Ca^{2+} -dependent chloride channels (CaCC) in plasma membrane leads to in Cl^- influx in *Xenopus* oocytes (b).

the COX8 signal sequence and the deletion of the first 24 a.a. of rhodopsin is the best option to achieve IMM targeting of ChR2.^{71,72} In case of successful targeting, the functionality of a MR in subcellular compartments also should be carefully examined. Works describing rhodopsins usually consider their activity in model systems. This gives an idea of the characteristics of the protein. However, it is widely known that the lipid environment²⁰⁰ and ion concentrations²⁰¹ significantly influence rhodopsins functioning. One should consider the photophysical properties of the rhodopsin, its compatibility with the cellular and organelle environment, and the specific requirements of the experimental design (*e.g.*, desired speed of response, wavelength of activation, *etc.*). Therefore, one cannot 100% guarantee the desired localization and unambiguously describe the features of protein functioning in a specific organelle. Another potential problem is that an overexpression of proteins in membranes of intracellular organelles which have complex three-dimensional organization (for example, IMM) could potentially lead to structural disruption and dysfunction of organelles.

Another limitation is related to the choice of transgene delivery vehicle. The most commonly used are adeno-associated viral (AAV) vectors.⁵ This type of vectors has a wide range of serotypes and unique tropism; however, their small DNA packaging size is a barrier for some tasks because the AAV genome does not exceed 4,800 bases.²⁰² In addition, AAV could induce an immune response and formation of anti-AAV antibodies, and some serotypes appear to be inefficient for

transduction, likely due to preexisting immunity.²⁰³ Another problem slowing down the potential clinical application of optogenetics is the immunogenicity of the optogenetic tools themselves, because these proteins are derived from non-human (bacterial, archaeal, and eukaryotic) origin, and humanization of these tools is also necessary.²⁰⁴

Most of the optogenetic results obtained with animals were carried out using classical models – *C. elegans*, zebrafish, or rodents.^{205–207} The ease of use of nematodes and zebrafish is due to their rapid development cycle, as well as the almost transparent properties of their body, which allows light to be easily delivered into their tissues. As for rodents, the stimulation of their brain neurons is easily achievable due to a smaller amount of brain tissue however, transferring technologies to the human brain requires significant optimization.²⁰⁸

As mentioned above, the parameters of light activation play an important role in optogenetics. The association between light parameters (such as wavelength, intensity, and duration of illumination) and rhodopsin activity is quite well-established.³¹ Rhodopsins undergo a photocycle upon photon absorption, which is a critical aspect of their functionality. The specifics of this photocycle, including its duration and the resulting biological effect, vary among different rhodopsin types. The precision of the control is influenced by the specific characteristics of the rhodopsin, the light source used, and the biological context. The response time can vary, but typically, rhodopsin activation occurs rapidly upon light exposure. Thus, to determine the duration of illumination for rhodopsin activation and



maintenance of its activity one should consider the photocycle duration of the specific rhodopsin, the desired biological outcome, and the cellular context.

In order to achieve the desired effect and reduce photo- and thermal tissue damage, the light delivery strategy, spectrum, output power, and other parameters must be precisely controlled.⁵ When operating at the level of tissues or the whole organism, the factor of light transmission should be taken into account. The intensity in the visible range drops by about 10 times when passing one millimeter deep into tissues.²⁰⁹ A red-shift of light for optogenetic stimulation allows deeper penetration into tissue layers and causes less photodamage.²¹⁰ In some cases, it is possible to activate optogenetic tools with two-photon or even three-photon excitation²¹¹ using infrared light with a particularly precise way of focusing. In this case, most of the radiation is scattered over a large volume, and the greatest intensity occurs in a small area at a selected point in the tissue. This approach allows one to perform an optogenetic manipulation within a small area, up to a single cell, and has been used, for example, to map neurons in a brain of living mice.²¹² However, even infrared light does not penetrate well into a human brain, therefore some light delivery devices may assist in overcoming this limitation. Thus, bringing light to deep-lying tissues is a rather difficult task. Such integration into tissues can be accompanied by cell damage, scarring, or infection, as well as technical difficulties during manipulation.²¹³ Nevertheless, a part of these problems can be avoided by creating thinner and more flexible optical fibers intended for implantation in tissues²¹⁴ or by using miniaturized, biocompatible, implantable LEDs.^{62,64,65} A good example is an epidural implant to deliver light into the spinal cord.²¹⁴ This implant was well tolerated by mice and did not affect their behavioral and motor activity.

Taken together, the organelle optogenetic-approach shares challenges with classical optogenetics: light delivery, gene modification of targeted cells, and others, and has some specific problems concerning organelle targeting of optogenetic tools. Despite this, unique opportunities for organelle manipulation with light are already promising for fundamental research and clinics.

Organelle optogenetics for basic research

Subcellular optogenetics is an emerging new field. It is considerably younger than optogenetics of excitable cells. Nevertheless, it is already clear that organelle optogenetics offers unique opportunities for basic research on cell physiology through the control of physicochemical cellular parameters. Fast and reversible manipulation of organelle ion gradients by light provides unique opportunities to study processes which are difficult to model solely by classical chemical approaches.

Cytosol pH regulation by plasma membrane-expressed MR proton pumps is an attractive approach to studying the role of intracellular pH in various processes. Local plasma membrane dynamics and cell motility could be studied.⁶⁷ In addition, the role of pH in cell differentiation,⁶⁰ cell cycle progression¹¹² and cell death induction⁶⁸ could be deciphered.

In mitochondria, expression of channelrhodopsins is an attractive tool for influencing OXPHOS and ATP production, modelling mitochondrial preconditioning, and mitochondrial-induced cell death.⁷² Optogenetic influence on the mitochondrial calcium levels could become a perspective tool to study the role of mitochondria in calcium signaling and calcium storage in neurons and other cells.⁷¹ Proton pump expression in IMM provides an opportunity to energize mitochondria in order to study its role in cell differentiation, stress-tolerance,⁷³ cell death,⁷² and aging.²¹⁵

Lysosomal proton pumps are an attractive tool to study lysosome function and a number of cellular processes, controlled by lysosomes.^{147,173} Endosomes alkalization by MR optogenetics interfered with the internalization of the AMPA receptor at active synapses and blocked motor learning.⁷⁰ MRs, expressed in synaptic vesicles, is a new tool for studying mechanisms of neurotransmission and the control of function of certain synapses.⁶⁹

The expression of channelrhodopsins in ER allows manipulating the concentration of intracellular calcium, one of the most important secondary messengers in the cell.⁷⁸ The intracellular Ca²⁺ release from ER/SR, and the subsequent activation of other internal Ca²⁺ signaling cascades such as calcium-induced calcium release or the store-operated Ca²⁺ entry can be studied.⁷⁷ In addition, it will be possible to study more accurately the impact of optogenetic changes of intracellular calcium levels on the process of myogenesis.¹⁰⁹ In addition, ER optogenetics allows studying the importance of calcium stores in dendritic spines in more detail, and it may provide insight into synaptic plasticity,²¹⁶ the role of dendritic spines during development, in stress, and neurodegenerative diseases.^{217,218} Thus, further improvements in the field of organelle optogenetics methodology will allow the manipulation of intracellular Ca²⁺ in neurobiology as well.

Organelle optogenetics provides researchers with unique tools for cell physiology studies under normal and pathologic conditions. Cell lines with organelle-expressed MRs could become a suitable model of organelle-related pathologies for studying their molecular mechanisms and testing potential therapies.

Clinical perspectives of organelle (intracellular) optogenetics

A visual function recovery is now an impressive example of the successful implementation of optogenetic technologies in clinics. It is an important step towards the medical application of optogenetics.²¹⁹ Attempts to restore photosensitivity in retinal degenerative disease models based on channelrhodopsin ChR2 or halorhodopsin eNpHR have been made since the beginning of optogenetics.^{220–222} Several clinical trials are currently underway on the use of optogenetic tools in the treatment of retinitis pigmentosa and retinal dystrophy using ChR2 (NCT02556736), Chrimson (NCT03326336), and Chronos (NCT04278131). Most recently, the first case of partial vision recovery in a patient after optogenetic therapy was reported.²²³

Hearing recovery is another promising application of optogenetics which may be considered as a potential alternative to



electrical cochlear implants.^{224,225} Successful restoration of auditory activity has been shown in rodents through the expression of Chr2^{64,226} and Chronos.²²⁷ Using animal models, optogenetics was utilized to stimulate regeneration of muscles, recovery of movements, treatment of muscle paralysis,^{228,229} treatment of heart diseases using light-induced stimulation of the heart muscle,^{230–233} and even offered new opportunities for the treatment of neurodegenerative diseases.²³⁴

Recently, a photosynthetic thylakoid-based system was efficiently used to increase cellular ATP levels and provide the regeneration of mice joint tissues.²³⁵ It may be considered as a proof-of-principle study showing that light-induced ATP synthesis in mammals is very promising. Such stimulation of bioenergetics may be also achieved by mitochondria-targeted MRs. Their targeting into energy-deficient tissues is another perspective application.

Organelle-based optogenetics is now at an earlier phase of development than its plasma-membrane-based counterpart. Still, there are some intriguing results that may be developed towards clinical applications in the near future. Using mitochondrial Chr2, researchers were able to manipulate the spontaneous beating of cardiomyocytes and stop it by light, which could be a step towards optogenetic cardiac stimulation approaches.⁷¹ Another application of mitochondrial MRs, proton pumps, which in contrast to Chr2 increase MMP, was proposed to activate mitochondria in T-lymphocytes, the cells which are devoted to cancer cell elimination but suffer from a low-oxygen environment inside a tumor.⁷⁴ This strategy is a potential optogenetic tool for the improvement of the chimeric antigen receptor T-cell therapy.²³⁶ MRs, especially proton pumps, expressed in lysosomes, could be tested as a potential optogenetic strategy to compensate for lysosome dysfunction in certain lysosomal storage diseases.⁶⁹ ER-targeted MRs are perspective tools for optogenetic control of muscle contraction.⁷⁷ Finally, synaptic vesicles-directed MRs could potentially improve neurotransmission.⁶⁹

Taking all of this into account, we can conclude that an organelle MR-based optogenetic approach may help to develop novel therapeutic strategies for a number of cardiac, metabolic, and neurologic disorders, as well as cancer.

Thus, organelle optogenetics is a relatively young, but rapidly developing approach offering amazing opportunities to control different cell functions in a precise and non-invasive way. Optogenetic manipulations with MMP, pH of lysosomes, endosomes, synaptic vesicles, cytosol, mitochondrial, and ER calcium concentration were already demonstrated and proved their efficiency. The field has tremendous potential for further development, despite some challenges in protein targeting, light penetration or light delivery. Certainly, an expanding toolkit will considerably enhance the development of intracellular optogenetics.

Author contributions

A. D. V. designed and wrote the manuscript. S. M. B. contributed to the “Mitochondria: optogenetic control of mitochondrial

membrane potential” section. D. F. B. and N. S. I. contributed to the “Lysosomes and endosomes: optogenetic control of pH and proteolysis” and “Synaptic vesicles: optogenetic control of neurotransmission” sections. A. P. P., A. V. V. and A. E. M. contributed to the “Endoplasmic reticulum: optogenetic control of calcium signaling” section. V. N. U. and E. V. Z. contributed to the “Structure and functions of microbial rhodopsins” and “Abbreviated (un)structural overview of optogenetics” sections. F. M. T. contributed to the “Advantages of MR-based optogenetic approaches” section. S. M. B. and F. M. T. contributed to the “Challenges of MR-based optogenetic approaches” section. S. M. B., D. F. B. and A. P. P. contributed to the “Organelle optogenetics for basic research” and “Clinical perspectives of organelle (intracellular) optogenetics” sections. S. V. N., A. O. B., and A. V. V., A. I. K., V. N. U., E. B. and V. I. B. edited the text of the manuscript. V. N. U., A. V. V., A. I. K., and V. I. B. managed the project. E. B. provided general support for this work. V. I. G. supervised the project and contributed to all the sections of the manuscript.

Conflicts of interest

The authors declare that they have no conflict of interest.

Acknowledgements

Preparation of the sections “Plasma membrane: membrane potential and metabolic control”, “Mitochondria: optogenetic control of mitochondrial membrane potential”, “Strategies of MR organelle targeting”, “Advantages of MR-based optogenetic approaches” and “Challenges of MR-based optogenetic approaches” was done with the support from the Russian Science Foundation (RSF) Project 21-64-00018. A. V. V. and E. V. Z. acknowledge the support from the Ministry of Science and Higher Education of the Russian Federation (agreement # 075-03-2024-117, project FSMG-2021-0002, sections “Endoplasmic reticulum: optogenetic control of calcium signaling” and “Structure and functions of microbial rhodopsins”). N. S. I. acknowledges the Ministry of Science and Higher Education of the Russian Federation (agreement # 075-03-2024-117, project FSMG-2024-0012, section “Lysosomes and endosomes: optogenetic control of pH and proteolysis” and “Synaptic vesicles: optogenetic control of neurotransmission”). A. D. V. acknowledges the support from the Ministry of Science and Higher Education of the Russian Federation (Agreement # 075-01593-23-04, Project 720000F.99.1.BN62AA40000, sections “Organelle optogenetics for basic research” and “Clinical perspectives of organelle (intracellular) optogenetics”).

References

- 1 K. Deisseroth, *Nat. Methods*, 2011, **8**, 26–29.
- 2 B. R. Rost, F. Schneider-Warme, D. Schmitz and P. Hegemann, *Neuron*, 2017, **96**, 572–603.



- 3 A. Alekseev, V. Gordeliy and E. Bamberg, *Rhodopsin*, 2022, pp. 71–100.
- 4 E. S. Boyden, F. Zhang, E. Bamberg, G. Nagel and K. Deisseroth, *Nat. Neurosci.*, 2005, **8**, 1263–1268.
- 5 V. Emiliani, E. Entcheva, R. Hedrich, P. Hegemann, K. R. Konrad, C. Lüscher, M. Mahn, Z. H. Pan, R. R. Sims, J. Vierock and O. Yizhar, *Nat. Rev. Methods Primers*, 2022, DOI: [10.1038/s43586-022-00136-4](https://doi.org/10.1038/s43586-022-00136-4).
- 6 G. Nagel, T. Szellas, W. Huhn, S. Kateriya, N. Adeishvili, P. Berthold, D. Ollig, P. Hegemann and E. Bamberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 13940–13945.
- 7 K. Deisseroth, *Nat. Neurosci.*, 2015, **18**, 1213–1225.
- 8 I. Gushchin and V. Gordeliy, *Subcell. Biochem.*, 2018, **87**, 19–56.
- 9 V. Gordeliy, K. Kovalev, E. Bamberg, F. Rodriguez-Valera, E. Zinovev, D. Zabelskii, A. Alekseev, I. Rosselli, R. Gushchin and I. Okhrimenko, *Rhodopsin*, 2022, pp. 1–52.
- 10 P. Tan, L. He, Y. Huang and Y. Zhou, *Physiol. Rev.*, 2022, **102**, 1263–1325.
- 11 A. A. M. Fischer, M. M. Kramer, G. Radziwill and W. Weber, *Curr. Opin. Chem. Biol.*, 2022, **70**, 102196.
- 12 G. Rivera-cancel, L. B. Motta-mena and K. H. Gardner, *Biochemistry*, 2012, **51**, 10024–10034.
- 13 B. L. Sinnen, A. B. Bowen, J. S. Forte, B. G. Hiester, K. C. Crosby, E. S. Gibson, M. L. Dell'Acqua and M. J. Kennedy, *Neuron*, 2017, **93**, 646–660.e5.
- 14 L. J. Bugaj, D. P. Spelke, C. K. Mesuda, M. Varedi, R. S. Kane and D. V. Schaffer, *Nat. Commun.*, 2015, **6**, DOI: [10.1038/ncomms7898](https://doi.org/10.1038/ncomms7898).
- 15 P. Van Bergeijk, M. Adrian, C. C. Hoogenraad and L. C. Kapitein, *Nature*, 2015, **518**, 111–114.
- 16 J. E. Toettcher, O. D. Weiner and W. A. Lim, *Cell*, 2013, **155**, 1422–1434.
- 17 R. M. Hughes, D. J. Freeman, K. N. Lamb, R. M. Pollet, W. J. Smith and D. S. Lawrence, *Angew. Chem., Int. Ed.*, 2015, **54**, 12064–12068.
- 18 E. Dine and J. E. Toettcher, *Biochemistry*, 2018, **57**, 2432–2436.
- 19 E. Alghoul, J. Basbous and A. Constantinou, *STAR Protoc.*, 2021, **2**, 100677.
- 20 A. Rademacher, F. Erdel, R. Weinmann and K. Rippe, *Methods Mol. Biol.*, 2023, **2563**, 395–411.
- 21 B. Y. Chow, X. Han, A. S. Dobry, X. Qian, A. S. Chuong, M. Li, M. A. Henninger, G. M. Belfort, Y. Lin, P. E. Monahan and E. S. Boyden, *Nature*, 2010, **463**, 98–102.
- 22 B. R. Rost, J. Wietek, O. Yizhar and D. Schmitz, *Nat. Neurosci.*, 2022, **25**, 984–998.
- 23 M. Garita-Hernandez, L. Guibbal, L. Tualbi, F. Routet, A. Chaffiol, C. Winckler, M. Harinquet, C. Robert, S. Fouquet, S. Bellow, J. A. Sahel, O. Goureau, J. Duebel and D. Dalkara, *Front. Neurosci.*, 2018, **12**, 789.
- 24 V. Gradinaru, F. Zhang, C. Ramakrishnan, J. Mattis, R. Prakash, I. Diester, I. Goshen, K. R. Thompson and K. Deisseroth, *Cell*, 2010, **141**, 154–165.
- 25 M. Engelhard, *Methods Mol. Biol.*, 2022, **2501**, 53–69.
- 26 E. G. Govorunova, O. A. Sineshchekov, H. Li and J. L. Spudich, *Annu. Rev. Biochem.*, 2017, **86**, 845–872.
- 27 O. P. Ernst, D. T. Lodowski, M. Elstner, P. Hegemann, L. S. Brown and H. Kandori, *Chem. Rev.*, 2014, **114**, 126–163.
- 28 T. Kouyama and M. Murakami, *Photochem. Photobiol. Sci.*, 2010, **9**, 1458–1465.
- 29 J. P. Klare, I. Chizhov and M. Engelhard, *Results Probl. Cell Differ.*, 2008, **45**, 73–122.
- 30 J. L. Spudich, C. S. Yang, K. H. Jung and E. N. Spudich, *Annu. Rev. Cell Dev. Biol.*, 2000, **16**, 365–392.
- 31 V. Gordeliy, K. Kovalev, E. Bamberg, F. Rodriguez-Valera, E. Zinovev, D. Zabelskii, A. Alekseev, R. Rosselli, I. Gushchin and I. Okhrimenko, *Methods Mol. Biol.*, 2022, **2501**, 1–52.
- 32 L. S. Brown, *Biochim. Biophys. Acta*, 2014, **1837**, 553–561.
- 33 H. Luecke, B. Schobert, J.-P. Cartailler, H.-T. Richter, A. Rosengarth, R. Needleman and J. K. Lanyi, *J. Mol. Biol.*, 2000, **300**, 1237–1255.
- 34 Z. Obradovic, K. Peng, S. Vucetic, P. Radivojac and A. K. Dunker, *Proteins: Struct., Funct., Bioinf.*, 2005, **61**, 176–182.
- 35 B. Mészáros, G. Erdős and Z. Dosztányi, *Nucleic Acids Res.*, 2018, **46**, W329–W337.
- 36 J. Bürgi, B. Xue, V. N. Uversky and F. G. Van Der Goot, *PLoS One*, 2016, DOI: [10.1371/JOURNAL.PONE.0158594](https://doi.org/10.1371/JOURNAL.PONE.0158594).
- 37 V. N. Uversky, *Prog. Mol. Biol. Transl. Sci.*, 2019, **166**, 1–17.
- 38 Q. Chen, M. Plasencia, Z. Li, S. Mukherjee, D. Patra, C. L. Chen, T. Klose, X. Q. Yao, A. A. Kossiakoff, L. Chang, P. C. Andrews and J. J. G. Tesmer, *Nature*, 2021, **595**, 600–605.
- 39 X. Fang, A. A. Peden, F. J. M. van Eeden and J. J. Malicki, *J. Cell Sci.*, 2021, **134**(6), DOI: [10.1242/JCS.254995](https://doi.org/10.1242/JCS.254995).
- 40 D. Feng, Z. Chen, K. Yang, S. Miao, B. Xu, Y. Kang, H. Xie and C. Zhao, *J. Biol. Chem.*, 2017, **292**, 1735–17386.
- 41 T. Y. Kim, T. Schlieter, S. Haase and U. Alexiev, *Eur. J. Cell Biol.*, 2012, **91**, 300–310.
- 42 S. T. Ahmad, M. Natochin, N. O. Artemyev and J. E. O'Tousa, *FASEB J.*, 2007, **21**, 449–455.
- 43 M. Ascano and P. R. Robinson, *Biochemistry*, 2006, **45**, 2398–2407.
- 44 A. V. Gourine, V. Kasymov, N. Marina, F. Tang, M. F. Figueiredo, S. Lane, A. G. Teschemacher, K. M. Spyer, K. Deisseroth and S. Kasparov, *Science*, 2010, **329**, 571–575.
- 45 Y. Oka, M. Ye and C. S. Zuker, *Nature*, 2015, **520**, 349–352.
- 46 C. Anacleto, L. Ferrari, E. Arrigoni, C. E. Bass, C. B. Saper, J. Lu and P. M. Fuller, *Nat. Neurosci.*, 2014, **17**, 1217–1224.
- 47 P. S. Kunwar, M. Zelikowsky, R. Remedios, H. Cai, M. Yilmaz, M. Meister and D. J. Anderson, *eLife*, 2015, **2015**, 1–30.
- 48 Z. Wu, A. E. Autry, J. F. Bergan, M. Watabe-uchida and C. G. Dulac, *Nature*, 2014, **509**, 325–330.
- 49 D. S. Roy, A. Arons, T. I. Mitchell, M. Pignatelli, T. J. Ryan and S. Tonegawa, *Nature*, 2016, **531**, 508–512.
- 50 B. M. Kenwood, J. L. Weaver, A. Bajwa, I. K. Poon, F. L. Byrne, B. A. Murrow, J. A. Calderone, L. Huang, A. S. Divakaruni, J. L. Tomsig, K. Okabe, R. H. Lo, G. C. Coleman, L. Columbus, Z. Yan, J. J. Saucerman, J. S. Smith, J. W. Holmes, K. R. Lynch, K. S. Ravichandran,



- S. Uchiyama, W. L. Santos, G. W. Rogers, M. D. Okusa, D. A. Bayliss and K. L. Hoehn, *Mol. Metab.*, 2014, **3**, 114–123.
- 51 Y. N. Antonenko, L. S. Khailova, D. A. Knorre, O. V. Markova, T. I. Rokitskaya, T. M. Ilyasova, I. I. Severina, E. A. Kotova, Y. E. Karavaeva, A. S. Prikhodko, F. F. Severin and V. P. Skulachev, *PLoS One*, 2013, **8**, 1–13.
- 52 N.-E. L. Saris, M. A. Andersson, R. Mikkola, L. C. Andersson, V. V. Teplova, P. A. Grigoriev and M. S. Salkinoja-Salonen, *Toxicol. Ind. Health*, 2009, **25**, 441–446.
- 53 K. A. I. T. Sundquist and S. C. Marks, *J. Bone Miner. Res.*, 1994, **9**, 1575–1582.
- 54 C. Doyno, D. M. Sobieraj and W. L. Baker, *Clin. Toxicol.*, 2021, **59**, 12–23.
- 55 D. R. Hochbaum, Y. Zhao, S. L. Farhi, N. Klapoetke, C. A. Werley, V. Kapoor, P. Zou, J. M. Kralj, D. MacLaurin, N. Smedemark-Margulies, J. L. Saulnier, G. L. Boulting, C. Straub, Y. K. Cho, M. Melkonian, G. K. S. Wong, D. J. Harrison, V. N. Murthy, B. L. Sabatini, E. S. Boyden, R. E. Campbell and A. E. Cohen, *Nat. Methods*, 2014, **11**, 825–833.
- 56 H. Kandori, *Front. Mol. Biosci.*, 2015, **2**, 150981.
- 57 E. G. Govorunova, O. A. Sineshchekov and J. L. Spudich, *Front. Cell. Neurosci.*, 2022, **15**, 800313.
- 58 J. Prigge and M. Wietek, *Optogenetics*, 2016, pp. 141–165.
- 59 F. Zhang, L. Wang, M. Brauner, J. F. Liewald, K. Kay, N. Watzke, P. G. Wood, E. Bamberg, G. Nagel, A. Gottschalk and K. Deisseroth, *Nature*, 2007, **446**, 633–641.
- 60 X. Han and E. S. Boyden, *PLoS One*, 2007, DOI: [10.1371/journal.pone.0000299](https://doi.org/10.1371/journal.pone.0000299).
- 61 K. P. Greenberg, A. Pham and F. S. Werblin, *Neuron*, 2011, **69**, 713–720.
- 62 L. Li, L. Lu, Y. Ren, G. Tang, Y. Zhao, X. Cai, Z. Shi, H. Ding, C. Liu, D. Cheng, Y. Xie, H. Wang, X. Fu, L. Yin, M. Luo and X. Sheng, *Nat. Commun.*, 2022, **13**, 1–14.
- 63 E. Papagiakoumou, *Biol. Cell*, 2013, **105**, 443–464.
- 64 D. Keppeler, M. Schwaerzle, T. Harczos, L. Jablonski, A. Dieter, B. Wolf, S. Ayub, C. Vogl, C. Wrobel, G. Hoch, K. Abdellatif, M. Jeschke, V. Rankovic, O. Paul, P. Ruther and T. Moser, *Sci. Transl. Med.*, 2020, **12**(553), DOI: [10.1126/scitranslmed.abb8086](https://doi.org/10.1126/scitranslmed.abb8086).
- 65 L. Yin, M. J. Rasch, Q. He, S. Wu, F. Dou and Y. Shu, *Cereb. Cortex*, 2015, bhv245.
- 66 O. A. Shemesh, D. Tanese, V. Zampini, C. Linghu, K. Piatkevich, E. Ronzitti, E. Papagiakoumou, E. S. Boyden and V. Emiliani, *Nat. Neurosci.*, 2017, **20**, 1796–1806.
- 67 C. E. T. Donahue, M. D. Siroky and K. A. White, *J. Am. Chem. Soc.*, 2021, **143**, 18877–18887.
- 68 S. Nakao, K. Kojima and Y. Sudo, *J. Am. Chem. Soc.*, 2022, **144**, 3771–3775.
- 69 B. R. Rost, F. Schneider, M. K. Grauel, C. Wozny, C. G. Bentz, A. Blessing, T. Rosenmund, T. J. Jentsch, D. Schmitz, P. Hegemann and C. Rosenmund, *Nat. Neurosci.*, 2015, **18**, 1845–1852.
- 70 W. Kakegawa, A. Katoh, S. Narumi, E. Miura, J. Motohashi, A. Takahashi and K. Kohda, *Neuron*, 2018, **99**, 985–998.e6.
- 71 T. Tkatch, E. Greotti, G. Baranauskas, D. Pendin, S. Roy, L. I. Nita, J. Wettmarshausen, M. Prigge, O. Yizhar, O. S. Shirihai, D. Fishman, M. Hershfinkel, I. A. Fleidervish, F. Perocchi, T. Pozzan and I. Sekler, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E5167–E5176.
- 72 P. Ernst, N. Xu, J. Qu, H. Chen, M. S. Goldberg, V. Darley-Usmar, J. J. Zhang, B. O'Rourke, X. Liu and L. Zhou, *Biophys. J.*, 2019, **117**, 631–645.
- 73 B. J. Berry, A. J. Trewin, A. S. Milliken, A. Baldzizhar, A. M. Amitrano, Y. Lim, M. Kim and A. P. Wojtovich, *EMBO Rep.*, 2020, **21**, 1–14.
- 74 A. M. Amitrano, B. J. Berry, K. Lim, K. Do Kim, R. E. Waugh, A. P. Wojtovich and M. Kim, *Front. Immunol.*, 2021, **12**.
- 75 K. Y. Hara, T. Wada, K. Kino, T. Asahi and N. Sawamura, *Sci. Rep.*, 2013, **3**, 1–4.
- 76 Y. Imai, T. Inoshita, H. Meng, K. Shiba-Fukushima, K. Y. Hara, N. Sawamura and N. Hattori, *Commun. Biol.*, 2019, **2**, 1–11.
- 77 T. Asano, H. Igarashi, T. Ishizuka and H. Yawo, *Front. Neurosci.*, 2018, **12**, 1–8.
- 78 A.-S. Eria-Oliveira, M. Folacci, A. A. Chassot, S. Fedou, N. Theze, D. Zabelskii, A. Alekseev, E. Bamberg, V. Gordeliy and G. Sandoz, *Nat. Commun.*, 2024, **15**, 65.
- 79 C. Smith, T. Frolinger, J. Brathwaite, S. Sims and G. M. Pasinetti, *Commun. Biol.*, 2018, **1**, 1–8.
- 80 K. M. Daicho, Y. Hirono-Hara, H. Kikukawa, K. Tamura and K. Y. Hara, *Microb. Cell Fact.*, 2024, **23**, 4.
- 81 A. Peterson, K. Baskett, W. C. Ratcliff and A. Burnett, *Curr. Biol.*, 2024, **34**(3), 648–654.
- 82 A. Vlasova, A. Polyakova, A. Gromova, S. Dolotova, S. Bukhalovich, D. Bagaeva, N. Bondarev, F. Tsybrov, K. Kovalev, A. Mikhailov, D. Sidorov, A. Bogorodskiy, N. Ilyinsky, A. Kuklin, A. Vlasov, V. Borshevskiy and V. Ivanovich, *Int. J. Biol. Macromol.*, 2023, **242**, 124949.
- 83 A. Hoffmann, V. Hildebrandt, J. Heberle and G. Boldt, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 9367–9371.
- 84 Y. Imai, T. Inoshita, H. Meng, K. Shiba-Fukushima, K. Y. Hara, N. Sawamura and N. Hattori, *Commun. Biol.*, 2019, **2**, 1–11.
- 85 B. J. Berry, A. J. Trewin, A. M. Amitrano, M. Kim and A. P. Wojtovich, *J. Mol. Biol.*, 2018, **430**, 3873–3891.
- 86 B. J. Berry, A. Vodičková, A. Müller-eigner, C. Meng, C. Ludwig, M. Kaeberlein, S. Peleg and A. P. Wojtovich, *Nat. Aging*, 2023, **3**, 157–161.
- 87 D. J. Klionsky, *et al.*, *Autophagy*, 2012, **8**, 445–544.
- 88 V. Gradinaru, F. Zhang, C. Ramakrishnan, J. Mattis, R. Prakash, I. Diester, I. Goshen, K. R. Thompson and K. Deisseroth, *Cell*, 2010, **141**, 154–165.
- 89 J. Deubner, P. Coulon and I. Diester, *Curr. Opin. Struct. Biol.*, 2019, **57**, 157–163.
- 90 L. H. Tai, A. M. Lee, N. Benavidez, A. Bonci and L. Wilbrecht, *Nat. Neurosci.*, 2012, **15**, 1281–1289.
- 91 J. D. Lenz and M. K. Lobo, *Behav. Brain Res.*, 2013, **255**, 44–54.
- 92 R. T. LaLumiere, *Front. Behav. Neurosci.*, 2014, **8**, 1–7.
- 93 D. Riga, M. R. Matos, A. Glas, A. B. Smit, S. Spijker and M. C. Van den Oever, *Front. Syst. Neurosci.*, 2014, **8**, 1–19.



- 94 X. Liu, S. Ramirez, P. T. Pang, C. B. Puryear, A. Govindarajan, K. Deisseroth and S. Tonegawa, *Nature*, 2012, **484**, 381–385.
- 95 G. Etter, S. van der Veldt, F. Manseau, I. Zarrinkoub, E. Trillaud-Doppia and S. Williams, *Nat. Commun.*, 2019, **10**, 1–11.
- 96 V. Gradinaru, K. R. Thompson and K. Deisseroth, *Brain Cell Biol.*, 2008, **36**, 129–139.
- 97 I. Nilsson, P. Lara, T. Hessa, A. E. Johnson, G. Von Heijne and A. L. Karamyshev, *J. Mol. Biol.*, 2015, **427**, 1191–1201.
- 98 C. Grimm, A. Silapetere, A. Vogt, Y. A. Bernal Sierra and P. Hegemann, *Sci. Rep.*, 2018, **8**, 1–12.
- 99 V. Shevchenko, T. Mager, K. Kovalev, V. Polovinkin, A. Alekseev, J. Juettner, I. Chizhov, C. Bamann, C. Vavourakis, R. Ghai, I. Gushchin, V. Borshchevskiy, A. Rogachev, I. Melnikov, A. Popov, T. Balandin, F. Rodriguez-Valera, D. J. Manstein, G. Bueldt, E. Bamberg and V. Gordeliy, *Sci. Adv.*, 2017, **3**, 1–11.
- 100 K. Inoue, *Bull. Chem. Soc. Jpn.*, 2016, **89**, 1416–1424.
- 101 C. Bamann, G. Nagel, E. Bamberg and J. W. Goethe-universita, *Curr. Opin. Neurobiol.*, 2010, **20**, 610–616.
- 102 I. Gushchin, V. Shevchenko, V. Polovinkin, K. Kovalev, A. Alekseev, E. Round, V. Borshchevskiy, T. Balandin, A. Popov, T. Gensch, C. Fahlke, C. Bamann, D. Willbold, G. Büldt, E. Bamberg and V. Gordeliy, *Nat. Struct. Mol. Biol.*, 2015, **22**, 390–396.
- 103 X. Han, B. Y. Chow, H. Zhou, N. C. Klapoetke, A. Chuong, R. Rajimehr, A. Yang, J. W. Baratta, V. Michael, R. Desimone and E. S. Boyden, *Front. Syst. Neurosci.*, 2011, **5**, 1–8.
- 104 D. Zabelskii, N. Dmitrieva, O. Volkov, V. Shevchenko, K. Kovalev, T. Balandin, D. Soloviov, R. Astashkin, E. Zinovev, A. Alekseev, E. Round, V. Polovinkin, I. Chizhov, A. Rogachev, I. Okhrimenko, V. Borshchevskiy, V. Chupin, G. Büldt, N. Yutin, E. Bamberg, E. Koonin and V. Gordeliy, *Commun. Biol.*, 2021, **4**(1), DOI: [10.1038/s42003-021-02326-4](https://doi.org/10.1038/s42003-021-02326-4).
- 105 E. G. Govorunova, O. A. Sineshchekov, R. Janz, X. Liu and J. L. Spudich, *Science*, 2015, **349**, 647–650.
- 106 A. Berndt, S. Y. Lee, C. Ramakrishnan and K. Deisseroth, *Science*, 2014, **23**, 1509–1511.
- 107 E. G. Govorunova, Y. Gou, O. A. Sineshchekov, H. Li, X. Lu, Y. Wang, L. S. Brown, F. St-pierre, M. Xue and J. L. Spudich, *Nat. Neurosci.*, 2022, **25**, 967–974.
- 108 T. Asano, T. Ishizua and H. yawo, *Biotechnol. Bioeng.*, 2012, **109**, 199–204.
- 109 T. Asano, T. Ishizuka, K. Morishima and H. yawo, *Sci. Rep.*, 2015, **5**, 8317.
- 110 L. M. Koch, E. S. Birkeland, S. Battaglion, X. Helle, M. Meerang, S. Hiltbrunner, A. J. Ibáñez, M. Peter, A. Curioni-Fontecedro, I. Opitz and R. Dechant, *Nat. Metab.*, 2020, **2**, 1212–1222.
- 111 C. Stock and A. Schwab, *Pflugers Arch.*, 2009, **458**, 981–992.
- 112 C. Frantz, G. Barreiro, L. Dominguez, X. Chen, R. Eddy, J. Condeelis, M. J. S. Kelly, M. P. Jacobson and D. L. Barber, *J. Cell Biol.*, 2008, **183**, 865–879.
- 113 M. Oginuma, Y. Harima, O. A. Tarazona, M. Diaz-Cuadros, A. Michaut, T. Ishitani, F. Xiong and O. Pourquié, *Nature*, 2020, **584**, 98–101.
- 114 M. P. Mattson, M. Gleichmann and A. Cheng, *Neuron*, 2008, **60**, 748–766.
- 115 H. N. Carter, C. C. W. Chen and D. A. Hood, *Physiology*, 2015, **30**, 208–223.
- 116 R. K. Naviaux, *Eur J. Pediatr.*, 2000, **159**, 219–226.
- 117 S. Vyas, E. Zaganjor and M. C. Haigis, *Cell*, 2016, **166**, 555–566.
- 118 M. T. Lin and M. F. Beal, *Nature*, 2006, **443**, 787–795.
- 119 K. Boengler, M. Kosiol, M. Mayr, R. Schulz and S. Rohrbach, *J. Cachexia Sarcopenia Muscle*, 2017, 349–369.
- 120 L. D. Zorova, V. A. Popkov, E. Y. Plotnikov, D. N. Silachev, I. B. Pevzner, S. S. Jankauskas, V. A. Babenko, S. D. Zorov, A. V. Balakireva, M. Juhaszova, S. J. Sollott and D. B. Zorov, *Anal. Biochem.*, 2018, **552**, 50–59.
- 121 J. Suski, M. Lebieczinska, M. Bonora, P. Pinton, J. Duszynski and M. R. Wieckowski, in *Mitochondrial Bioenergetics*, ed. C. M. Palmeira and A. J. Moreno, 2018, vol. 1782.
- 122 K. Demishtein-zohary and A. Azem, *Cell Tissue Res.*, 2017, 33–41.
- 123 C. Giorgi, S. Marchi and P. Pinton, *Nat. Rev. Mol. Cell Biol.*, 2018, **19**(11), 713–730.
- 124 S. Orrenius, B. Zhivotovsky and P. Nicotera, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 552–565.
- 125 H. K. Baumgartner, J. V. Gerasimenko, C. Thorne, P. Ferdek, T. Pozzan, A. V. Tepikin, O. H. Petersen, R. Sutton, A. J. M. Watson and O. V. Gerasimenko, *J. Biol. Chem.*, 2009, **284**, 20796–20803.
- 126 E. Kummer and N. Ban, *Nat. Rev. Mol. Cell Biol.*, 2021, **22**, 307–325.
- 127 T. Kleine, U. G. Maier and D. Leister, *Annu. Rev. Plant Biol.*, 2009, **60**, 115–138.
- 128 N. Wiedemann and N. Pfanner, *Annu. Rev. Biochem.*, 2017, **86**, 685–714.
- 129 M. C. Avendaño-Monsalve, J. C. Ponce-Rojas and S. Funes, *Biol. Chem.*, 2020, **401**, 645–661.
- 130 N. Pfanner, B. Warscheid and N. Wiedemann, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 267–284.
- 131 D. Mokranjac and W. Neupert, *Biochim. Biophys. Acta, Bioenerg.*, 2010, **1797**, 1045–1054.
- 132 B. Homberg, P. Rehling and L. D. Cruz-Zaragoza, *Trends Cell Biol.*, 2023, **33**, 765–772.
- 133 B. J. Berry and A. P. Wojtovich, *FEBS J.*, 2020, **287**, 4544–4556.
- 134 E. C. Hurt, B. Pesold-Hurt and G. Schatz, *FEBS Lett.*, 1984, **178**, 306–310.
- 135 A. E. Palmer, M. Giacomello, T. Kortemme, S. A. Hires, V. Lev-Ram, D. Baker and R. Y. Tsien, *Chem. Biol.*, 2006, **13**, 521–530.
- 136 S. A. Graf, S. E. Haigh, E. D. Corson and O. S. Shirihai, *J. Biol. Chem.*, 2004, **279**, 42954–42963.
- 137 C. Gieffers, F. Koriath, P. Heimann, C. Ungermann and J. Frey, *Exp. Cell Res.*, 1997, **232**, 395–399.
- 138 K. Y. Ma, M. R. Fokkens, F. Reggiori, M. Mari and D. S. Verbeek, *Transl. Neurodegener.*, 2021, **10**, 1–17.
- 139 S. Demine, P. Renard and T. Arnould, *Cells*, 2019, **8**(8), DOI: [10.3390/cells8080795](https://doi.org/10.3390/cells8080795).



- 140 E. J. Blott and G. M. Griffiths, *Nat. Rev. Mol. Cell Biol.*, 2002, **3**, 122–131.
- 141 J. P. Luzio, P. R. Pryor and N. A. Bright, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 622–632.
- 142 P. Saftig and J. Klumperman, *Nat. Rev. Mol. Cell Biol.*, 2009, **10**, 623–635.
- 143 S. R. Bonam, F. Wang and S. Muller, *Nat. Rev. Drug Discovery*, 2019, **18**, 923–948.
- 144 J. A. Mindell, *Annu. Rev. Physiol.*, 2012, **74**, 69–86.
- 145 Y. B. Hu, E. B. Dammer, R. J. Ren and G. Wang, *Transl. Neurodegener.*, 2015, **4**, 1–10.
- 146 Q. Song, B. Meng, H. Xu and Z. Mao, *Transl. Neurodegener.*, 2020, **9**, 1–14.
- 147 A. Ballabio and J. S. Bonifacino, *Nat. Rev. Mol. Cell Biol.*, 2019, **21**, 101–118.
- 148 J. Gilleron, J. M. Gerdes and A. Zeigerer, *Traffic*, 2019, **20**, 552–570.
- 149 P. Boya and G. Kroemer, *Oncogene*, 2008, **27**, 6434–6451.
- 150 H. Appelqvist, P. Wäster, K. Kågedal and K. Öllinger, *J. Mol. Cell Biol.*, 2013, **5**, 214–226.
- 151 T. Braulke and J. S. Bonifacino, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2009, **1793**, 605–614.
- 152 S. R. Carlsson, J. Roth, F. Pillar and M. Fukuda, *J. Biol. Chem.*, 1988, **263**, 18911–18919.
- 153 Y. Zhao, J. Ren, S. Padilla-Parra, E. E. Fry and D. I. Stuart, *Nat. Commun.*, 2014, **5**(1), DOI: [10.1038/ncomms5321](https://doi.org/10.1038/ncomms5321).
- 154 M. S. Pols and J. Klumperman, *Exp. Cell Res.*, 2009, **315**, 1584–1592.
- 155 A. Mironov and M. Pavelka, *The Golgi Apparatus*, 2008, vol. 13.
- 156 J. S. Bonifacino and L. M. Traub, *Annu. Rev. Biochem.*, 2003, **72**, 395–447.
- 157 J. S. Bonifacino and J. Lippincott-Schwartz, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 409–414.
- 158 D. L. Hogue, C. Nash, V. Ling and T. C. Hobman, *Biochem. J.*, 2002, **365**, 721–730.
- 159 S. Storch, S. Pohl and T. Braulke, *J. Biol. Chem.*, 2004, **279**, 53625–53634.
- 160 H. Schulze, T. Kolter and K. Sandhoff, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2009, **1793**, 674–683.
- 161 J. L. Jeger, *Mol. Biol. Rep.*, 2020, **47**, 9801–9810.
- 162 J. Huotari and A. Helenius, *EMBO J.*, 2011, **30**, 3481–3500.
- 163 A. Conte and S. Sigismund, *The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling*, Elsevier Inc., 2016, ch. 6, vol. 141.
- 164 F. R. Maxfield and D. J. Yamashiro, *Adv. Exp. Med. Biol.*, 1987, **225**, 189–198.
- 165 J. Rink, E. Ghigo, Y. Kalaidzidis and M. Zerial, *Cell*, 2005, **122**, 735–749.
- 166 Y. G. Zhao, P. Codogno and H. Zhang, *Nat. Rev. Mol. Cell Biol.*, 2021, **22**, 733–750.
- 167 J. P. Luzio, S. R. Gray and N. A. Bright, *Biochem. Soc. Trans.*, 2010, **38**, 1413–1416.
- 168 G. Parenti, D. L. Medina and A. Ballabio, *EMBO Mol. Med.*, 2021, **13**(2), e12836.
- 169 F. M. Platt, A. D'Azzo, B. L. Davidson, E. F. Neufeld and C. J. Tift, *Nat. Rev. Dis. Primers*, 2018, **4**(1), 27.
- 170 D. S. Rao, S. V. Bradley, P. D. Kumar, T. S. Hyun, D. Saint-Dic, K. Oravec-Wilson, C. G. Kleer and T. S. Ross, *Cancer Cell*, 2003, **3**, 471–482.
- 171 R. A. Nixon, *Neurobiol. Aging*, 2005, **26**, 373–382.
- 172 D. Wang, C. C. Chan, S. Cherry and P. R. Hiesinger, *Cell. Mol. Life Sci.*, 2013, **70**, 2919–2934.
- 173 N. S. Ilyinsky, S. M. Bukhalovich, D. F. Bagaeva, S. V. Nesterov, A. A. Alekseev, F. M. Tsybrov, A. O. Bogorodskiy, O. V. Moiseeva, A. D. Vlasova, K. V. Kovalev, A. E. Mikhailov, A. V. Rogachev, E. Bamberg, V. Ivanovich and V. I. Borshchevskiy, *bioRxiv*, 2023, preprint, DOI: [10.1101/2023.08.02.551716](https://doi.org/10.1101/2023.08.02.551716).
- 174 A. Vandewalle, F. Cluzeaud, K. C. Peng, M. Bens, A. Lüchow, W. Günther and T. J. Jentsch, *Am. J. Physiol.: Cell Physiol.*, 2001, **280**(2), DOI: [10.1152/AJPCELL.2001.280.2.C373](https://doi.org/10.1152/AJPCELL.2001.280.2.C373).
- 175 H. Xu and D. Ren, *Annu. Rev. Physiol.*, 2015, **77**, 57–80.
- 176 P. Li, M. Gu and H. Xu, *Trends Biochem. Sci.*, 2019, **44**, 110–124.
- 177 P. C. Trivedi, J. J. Bartlett and T. Pulinilkunnil, *Cells*, 2020, **9**, 1–35.
- 178 C. Meyer-Schwesinger, *Cell Tissue Res.*, 2021, **385**, 371–392.
- 179 T. C. Südhof, *Cell*, 2006, **127**, 671–673.
- 180 K. W. Beyenbach and H. Wiczorek, *J. Exp. Biol.*, 2006, **209**, 577–589.
- 181 M. Forgac, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 917–929.
- 182 J. Burré and W. Volkandt, *J. Neurochem.*, 2007, **101**, 1448–1462.
- 183 S. Wittig, M. Ganzella, M. Barth, S. Kostmann, D. Riedel, Á. Pérez-Lara, R. Jahn and C. Schmidt, *Nat. Commun.*, 2021, **12**, 858.
- 184 Y. Xu, X. Song, D. Wang, Y. Wang, P. Li and J. Li, *Mol. Brain*, 2021, **14**, 37.
- 185 Z. Taoufiq, M. Ninov, A. Villar-Briones, H.-Y. Wang, T. Sasaki, M. C. Roy, F. Beauchain, Y. Mori, T. Yoshida, S. Takamori, R. Jahn and T. Takahashi, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 33586–33596.
- 186 S.-H. Song and G. J. Augustine, *Mol. Cells*, 2015, **38**, 936–940.
- 187 S. L. Jackman, J. Turecek, J. E. Belinsky and W. G. Regehr, *Nature*, 2016, **529**, 88–91.
- 188 H. Liu, H. Bai, E. Hui, L. Yang, C. S. Evans, Z. Wang, S. E. Kwon and E. R. Chapman, *eLife*, 2014, **3**, DOI: [10.7554/eLife.01524](https://doi.org/10.7554/eLife.01524).
- 189 A. D. Blagoveshchenskaya, E. W. Hewitt and D. F. Cutler, *Di-Leucine Signals Mediate Targeting of Tyrosinase and Synaptotagmin to Synaptic-like Microvesicles within PC12 Cells*, 1999, vol. 10.
- 190 V. F. Prado and M. A. M. Prado, *Signals Involved in Targeting Membrane Proteins to Synaptic Vesicles*, 2002, vol. 22.
- 191 D. J. Adams, C. P. Arthur and M. H. B. Stowell, *Sci. Rep.*, 2015, **5**, 1–9.
- 192 D. S. Schwarz and M. D. Blower, *Cell. Mol. Life Sci.*, 2016, **73**, 79–94.
- 193 T. A. Rapoport, *Nature*, 2007, **450**, 663–669.
- 194 D. Burdakov, O. H. Petersen and A. Verkhratsky, *Cell Calcium*, 2005, **38**, 303–310.



- 195 J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Židek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli and D. Hassabis, *Nature*, 2021, **596**, 583–589.
- 196 R. Coronado, J. Morrisette, M. Sukhareva and D. M. Vaughan, *Am. J. Physiol.: Cell Physiol.*, 1994, **266**, C1485–C1504.
- 197 L. Wen, H. Wang, S. Tanimoto, R. Egawa, Y. Matsuzaka, H. Mushiake, T. Ishizuka and H. yawo, *PLoS One*, 2010, **5**(9), DOI: [10.1371/journal.pone.0012893](https://doi.org/10.1371/journal.pone.0012893).
- 198 K. Sushmita, S. Sharma, M. S. Kaushik and S. Kateriya, *Biophys. Physicobiol.*, 2023, **20**, e201008.
- 199 N. Wiedemann, A. E. Frazier and N. Pfanner, *J. Biol. Chem.*, 2004, **279**, 14473–14476.
- 200 O. Soubias, W. E. Teague, K. G. Hines and K. Gawrisch, *Biophys. J.*, 2015, **108**, 1125–1132.
- 201 I. S. Okhrimenko, K. Kovalev, L. E. Petrovskaya, N. S. Ilyinsky, A. A. Alekseev, E. Marin, T. I. Rokitskaya, Y. N. Antonenko, S. A. Siletsky, P. A. Popov, Y. A. Zagryadskaya, D. V. Soloviov, I. V. Chizhov, D. V. Zabelskii, Y. L. Ryzhykau, A. V. Vlasov, A. I. Kuklin, A. O. Bogorodskiy, A. E. Mikhailov, D. V. Sidorov, S. Bukhalovich, F. Tsybrov, S. Bukhdruker, A. D. Vlasova, V. I. Borshchevskiy, D. A. Dolgikh, M. P. Kirpichnikov, E. Bamberg and V. I. Gordeliy, *Commun. Chem.*, 2023, **6**, 1–16.
- 202 S. R. De Silva and A. T. Moore, *J. Physiol.*, 2022, **21**, 4623–4632.
- 203 S. D. Mendoza, Y. El-Shamayleh and G. D. Horwitz, *J. Neurophysiol.*, 2017, **117**, 2004–2013.
- 204 J. Wu, D. L. Prole, Y. Shen, Z. Lin, A. Gnanasekaran, Y. Liu, L. Chen, H. Zhou, S. R. W. Chen, Y. M. Usachev, C. W. Taylor and R. E. Campbell, *Biochem. J.*, 2014, **464**, 13–22.
- 205 A. Prabhakar, D. Vujovic, L. Cui, W. Olson and W. L. Id, *PLoS One*, 2019, **2**, 1–11.
- 206 Y. Kimura, C. Satou, S. Fujioka, W. Shoji, K. Umeda, T. Ishizuka and H. yawo, *Curr. Biol.*, 2013, **23**, 843–849.
- 207 J. F. Liewald, M. Brauner, G. J. Stephens, M. Bouhours, C. Schultheis, M. Zhen and A. Gottschalk, *Nat. Methods*, 2008, **5**, 895–902.
- 208 Y. Shen, R. E. Campbell, D. C. Cote and M.-E. Paquet, *Front. Neural Circuits*, 2020, **14**, 1–11.
- 209 W. Yang, L. Carrillo-Reid, Y. Bando, D. S. Peterka and R. Yuste, *eLife*, 2018, **7**, 1–21.
- 210 K. Lehtinen, M. S. Nokia and H. Takala, *Front. Cell. Neurosci.*, 2022, **15**, 1–20.
- 211 W. Zong, R. Wu, M. Li, Y. Hu, Y. Li, J. Li, H. Rong, H. Wu, Y. Xu, Y. Lu, H. Jia, M. Fan, Z. Zhou, Y. Zhang, A. Wang, L. Chen and H. Cheng, *Nat. Methods*, 2017, **14**, 713–719.
- 212 K. T. Newmaster, F. A. Kronman, Y. T. Wu and Y. Kim, *Front. Neuroanat.*, 2022, **15**, 1–19.
- 213 R. P. Bonin, F. Wang and M. Desrochers, *Mol. Pain*, 2016, **12**, 1–11.
- 214 M. R. B. Kim Tae-il, J. G. McCall, Y. Hwan Jung, X. Huang, E. R. Siuda, Y. Li, J. Song, Y. Min Song, H. An Pao, R.-H. Kim, C. Lu, S. Dan Lee, I.-S. Song, G. Shin, R. Al-Hasani, S. Kim, M. Peun Tan and Y. Huang, *Science*, 2013, **340**, 211–216.
- 215 B. J. Berry, A. Vodičková, A. Müller-eigner, C. Meng, C. Ludwig, M. Kaeberlein, S. Peleg and A. P. Wojtovich, *Nat. Aging*, 2023, **3**, 157–161.
- 216 T. Collin, A. Marty and I. Llano, *Curr. Opin. Neurobiol.*, 2005, **15**, 275–281.
- 217 M. Segal and E. Korkotian, *Neuroscientist*, 2016, **22**, 477–485.
- 218 M. Segal and E. Korkotian, *Front. Neuroanat.*, 2014, **8**, 1–7.
- 219 A. Bansal, S. Shikha and Y. Zhang, *Nat. Biomed. Eng.*, 2023, **7**(4), DOI: [10.1038/s41551-021-00829-3](https://doi.org/10.1038/s41551-021-00829-3).
- 220 V. Busskamp, J. Duebel, D. Balya, M. Fradot, T. J. Viney, S. Siegert, A. C. Groner, E. Cabuy, V. Forster, M. Seeliger, M. Biel, P. Humphries, M. Paques, S. Mohand-Said, D. Trono, K. Deisseroth, J. A. Sahel, S. Picaud and B. Roska, *Science*, 2010, **329**, 413–417.
- 221 P. S. Lagali, D. Balya, G. B. Awatramani, T. A. Münch, D. S. Kim, V. Busskamp, C. L. Cepko and B. Roska, *Nat. Neurosci.*, 2008, **11**, 667–675.
- 222 A. Bi, J. Cui, Y.-P. Ma, E. Olshevskaya, M. Pu, A. M. Dizhoor and Z.-H. Pan, *Neuron*, 2006, **50**, 23–33.
- 223 J. A. Sahel, E. Boulanger-Scemama, C. Pagot, A. Arleo, F. Galluppi, J. N. Martel, S. D. Esposti, A. Delaux, J. B. de Saint Aubert, C. de Montleau, E. Gutman, I. Audo, J. Duebel, S. Picaud, D. Dalkara, L. Blouin, M. Tael and B. Roska, *Nat. Med.*, 2021, **27**, 1223–1229.
- 224 J. A. Brant, D. O. Adewole, F. Vitale and D. K. Cullen, *Curr. Opin. Biotechnol.*, 2021, **72**, 131–138.
- 225 A. Dieter, D. Keppeler and T. Moser, *EMBO Mol. Med.*, 2020, **12**, 1–16.
- 226 V. H. Hernandez, A. Gehrt, K. Reuter, Z. Jing, M. Jeschke, A. M. Schulz, G. Hoch, M. Bartels, G. Vogt, C. W. Garnham, H. yawo, Y. Fukazawa, G. J. Augustine and E. Bamberg, *J. Clin. Invest.*, 2014, **124**, 1114–1129.
- 227 A. Mittring, T. Moser and A. Huet, *Brain Stimul.*, 2023, **16**, 466–483.
- 228 T. Bruegmann, T. Van Bremen, C. C. Vogt, T. Send, B. K. Fleischmann and P. Sasse, *Nat. Commun.*, 2015, **6**, 1–8.
- 229 P. Magown, B. Shettar, Y. Zhang and V. F. Rafuse, *Nat. Commun.*, 2015, **6**(1), DOI: [10.1038/ncomms9506](https://doi.org/10.1038/ncomms9506).
- 230 U. Nussinovitch and L. Gepstein, *Nat. Biotechnol.*, 2015, **33**, 750–754.
- 231 A. Arrenberg, D. Stainier, H. Baier and J. Huisken, *Science*, 2010, **330**, 971–974.
- 232 T. Bruegmann, D. Malan, M. Hesse, T. Beiert, C. J. Fuegemann, B. K. Fleischmann and P. Sasse, *Nat. Methods*, 2010, **7**, 897–900.
- 233 P. Sasse, M. Funken, T. Beiert and T. Bruegmann, *Front. Physiol.*, 2019, **10**, DOI: [10.3389/fphys.2019.00675](https://doi.org/10.3389/fphys.2019.00675).
- 234 P. Mirzayi, P. Shobeiri, A. Kalantari, G. Perry and N. Rezaei, *Mol. Brain*, 2022, **15**, 1–14.
- 235 P. Chen, X. Liu, C. Gu, P. Zhong, N. Song, M. Li, Z. Dai, X. Fang, Z. Liu, J. Zhang, R. Tang, S. Fan and X. Lin, *Nature*, 2022, **612**, 546–554.
- 236 A. M. Amitrano and M. Kim, *Immune Netw.*, 2023, **23**, e9.

